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ABSTRACT
Alzheimer’s disease (AD) is the most common form of dementia, and it currently
affects more than 50 million people worldwide. Much of the population develop lateonset AD after 65 and constitute more than 95% of the cases. Currently, there is no
definitive cure or way to slow down the progression of this disease that addresses the
neurodegeneration and loss of cognitive functions. Although the underlying cause of
AD is still unknown, the “amyloid cascade hypothesis” attributed it to the aggregation
of amyloid beta (Aβ) peptides and has been the focus for targeting most diseasemodifying drugs in clinical trials. However, emerging works suggest that the causal
effects of AD may not be limited to Aβ alone and that inhibition of its production can
lead to exacerbation of cognitive impairment in AD patients. The molecular pathways
affected in AD include loss of synapse, accumulation of oxidative DNA damage, and
impairment of protein synthesis, which are majorly affecting the ability of the brain to
form and store memory.
In this dissertation, our analysis using publicly available metabolomics data
showed that serum tyrosine level increases during aging and is also an
underappreciated biomarker for various neurocognitive, cardiovascular, and
metabolic diseases. Concomitantly, our bioinformatics analysis using publicly available
transcriptomics and brain proteomic data showed that tyrosyl-tRNA synthetase
(TyrRS) that activates tyrosine for protein synthesis and helps in DNA repair shows the
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highest expression in the cerebral cortex and is significantly reduced in the affected
brain regions of AD patients. Despite the correlation of brain protein levels of TyrRS
with human cognitive performance and AD disease progression, intriguingly, the brain
TyrRS levels did not correlate with any known biomarkers of neurodegeneration,
suggesting that brain TyrRS level is modulated through hitherto unknown factors and
mechanisms.
During our exploration to unravel the molecular mechanism and signaling
pathways that would potentially modulate neuronal TyrRS levels, we serendipitously
discovered that tyrosine itself is a potential causal agent that depletes TyrRS levels in
neurons. In contrast, dopamine - a tyrosine-derived neurotransmitter, stimulates the
de novo synthesis of neuronal TyrRS. Furthermore, we previously showed that tyrosine
inhibits nuclear TyrRS-mediated activation of the auto-poly-ADP-ribos(PAR)ylation of
poly-ADP-ribose polymerase 1 (PARP1). Intriguingly, inhibition of the auto-PARylation
of PARP1 ‘traps’ PARP1 on the damaged DNA and inhibits the repair of oxidative DNA
damage. Consistently, here we found that tyrosine depletes nuclear TyrRS and is a
potent inducer of neuronal oxidative DNA damage. Taken together, our findings in this
dissertation suggest that an age-associated increase in serum tyrosine level may have
causal effects not only in aging but also in various metabolic and neurocognitive
disorders, including AD.
We previously showed that resveratrol is a natural molecule that binds to
TyrRS. However, trans-resveratrol brought mixed outcomes in clinical trials, and the
molecular basis remained an unresolved scientific problem. In this work, we
discovered that trans-resveratrol (trans-RSV) that binds to TyrRS in a ‘tyrosine-like’
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conformation decreases TyrRS levels, causing oxidative DNA damage and
neurotoxicity. In contrast, cis-RSV that binds to TyrRS in a ‘tyrosine-free’ conformation
increased TyrRS levels, facilitated DNA repair, and provided neuroprotection in a
TyrRS-dependent manner. Our novel findings thus offer a possible explanation for
trans-RSV mediated detrimental effects such as increased brain volume loss in AD
patients, worsening memory in schizophrenia, and increased cardiovascular risk, like
the effect of high concentrations of trans-RSV that deplete TyrRS and cause
neurotoxicity. On the other hand, studies reporting low dose RSV reporting cognitive
benefits and protection from heart failure used doses equivalent to low
concentrations of trans-RSV that act like cis-RSV, increasing TyrRS and was
neuroprotective. In addition to explaining the apparent benefits associated with low
doses of trans-RSV, our work suggests that cis-RSV or the use of cis-RSV as a
pharmacophore may help develop drugs against age-associated neurological
disorders and metabolic diseases.
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CHAPTER 1
INTRODUCTION
Alzheimer's disease (AD) is currently considered an irreversible neurodegenerative
disorder characterized by progressive cognitive impairment. It is the leading cause of
dementia in the elderly, comprising 60-80% of the cases worldwide (“2018 Alzheimer’s
Disease Facts and Figures,” 2018). The incidence of AD doubles every five years after
65 years of age. At present, it affects around 50 million people worldwide (“2018
Alzheimer’s Disease Facts and Figures,” 2018; Brookmeyer et al., 2011). AD affects
women more than men, with two-thirds of total cases, but the reasons for this are
unknown (Brunnström & Englund, 2009; Nebel et al., 2018). German psychiatrist and
neurologist Alois Alzheimer first described AD in 1906 after a long-term study of a 51year-old female patient named Auguste Deter, who first visited him in November
1901. She was presented with memory, language, and other psychological issues such
as disorientation and hallucinations. Although these symptoms were sufficient to
classify the disease as dementia generally seen in the elderly, Dr. Alzheimer decided
to diagnose her as "presenile dementia" because she was very young to be diagnosed
with the 'classic' dementia. In addition, because Dr. Alzheimer had never seen a similar
case like hers, he decided to perform an autopsy of her brain after her death on April
8, 1906, after securing her family's permission. During the autopsy, he recorded
extensive atrophy, especially in the cortex -the central brain region linked to memory
and cognition.

Further analysis of the silver salt-stained brain tissue samples showed two types of
abnormal deposits - one outside the nerve cells (currently known as "amyloid
plaques") and the other inside (currently referred to as "neurofibrillary tangles
(NFTs)." Although similar deposits were observed before, Dr. Alzheimer was the first
to report such deposits in a young patient on November 4, 1906, at the 37th annual
conference of German psychiatrists, in Tübingen, Germany (Schorer, 1985; Stelzmann
et al., 1995). In short, Dr. Alzheimer's successful correlation of the anatomical findings
with the clinical behavioral observations earned his recognition in modern
neuropathology. Unfortunately, he died at 51 due to heart and kidney problems on
December 19, 1915 (Maurer et al., 1997).
AD is characterized by a deceptive onset and a steady decline in cognitive
functions. AD's clinical manifestations include a loss of episodic memory followed by
later impairments of complex attention, executive function, changes in personality,
judgment, and behavior (Hyman et al., 2012). A long preclinical phase characterizes
AD, and neurodegeneration is estimated to start 15-20 years before the onset of
clinical symptoms, during which pathological changes accumulate (Vermunt et al.,
2019). The long preclinical stage of disease, without the significant clinical pathology
definitive for AD, is the mild cognitive impairment (MCI) phase. As a result, when the
symptoms are pronounced enough and a diagnosis is made, significant
neurodegeneration results in irreversible damage that manifests as cognitive decline.
Thus, dementia due to AD results in significant and progressive disability throughout
the disease course, with an inevitable outcome of death generally occurring within 5–
12 years of onset of symptoms (Vermunt et al., 2019). As of today, there is no cure or
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a way to slow neurodegeneration in AD, and the only approved medications are aimed
at treating or modifying the symptoms.
1.1 Alzheimer's Disease Heritability
A small subset of AD cases results from autosomal dominant mutations and are
responsible for developing early-onset familial AD (FAD), constituting about 1% of all
AD cases. These mutations are found in three genes: APP (amyloid precursor protein),
PSEN1, and PSEN2 (presenilin 1 and 2). Presenilin 1 and 2 are subunits of the γsecretase complex that generate two amyloid-β (Aβ) peptides of length 40 and 42
(Aβ40 and Aβ42), and Aβ42 has a higher tendency to form aggregates (aka amyloid
plaques). Individuals with these specific mutations tend to develop AD well before age
65, typically around 30. Interestingly, individuals with trisomy 21, or an extra copy of
chromosome 21, are also prone to develop AD due to overexpression of the APP gene.
Reports indicate that most individuals with trisomy 21, or Down's Syndrome, develop
AD after age 40 due to higher amyloid plaque load (Head et al., 2012). However,
intriguingly, mice and rats do not produce Aβ peptides that aggregate similar to
human Aβ found in AD pathology. Mouse and human APP differ by 17 amino acids, 3
in the Aβ region, thus affecting its cleavage and aggregation (Hall & Roberson, 2012).
Therefore, to investigate AD pathology more accurately in a rodent model, transgenic
mice and rats were engineered using the FAD mutations to create more accurate
models for AD-related research. The pathogenic mutations in the Aβ-encoding gene
sequence are often located near the protease cleavage sites, which result in the
aberrant proteolytic processing of APP. The effects of APP mutations include increased
overall production of Aβ peptides, increased ratio of Aβ1-42/Aβ1-40, increased secretion
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of Aβ1-42 and Aβ1-40, and increased oligomerization. Consistently, transgenic rodent
models expressing human APP show elevated levels of Aβ1-42 along with Aβ deposits
(Rockenstein et al., 2001)
In contrast to FAD, much of the population develop late-onset AD (LOAD) after
age 65. These late-onset or sporadic AD (sAD) cases constitute more than 95% of
known cases in the population (Brunnström & Englund, 2009). Even though no single
genetic cause of sAD has been identified, genetic risk factors are associated with sAD.
The most prominent one is APOE, which encodes for apolipoprotein E (apoE). APOE
has three alleles, ε2, ε3, and ε4, where ε2 appears to be protective, ε3 neutral, and ε4
harmful. The most common allele is ε3, followed by ε4, and ε2 (Corbo & Scacchi,
1999). ε2 exerts its protective effect by decreasing the overall risk of developing sAD
and delaying onset (Reiman et al., 1996). ε4 lowers the age of onset and increases risk
in a dose-dependent manner. Individuals who are heterozygous or homozygous for ε4
have an increased risk, three and 15 times more likely to develop sAD than individuals
without a copy of the ε4 allele (Brouwers et al., 2008). The mechanism by which APOE
modulates risk is not well known.
1.2 Amyloid Cascade Hypothesis
Although the underlying cause of AD is not yet known, the "amyloid cascade
hypothesis" is a widely discussed pathological pathway. The amyloid cascade
hypothesis, introduced in 1992, suggested that increased production and aggregation
of Aβ1-42 result in AD due to the formation of plaques and NFTs that drive neuronal
death and dementia (Hardy & Higgins, 1992).
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1.2.1 Amyloid Precursor Protein Processing
The amyloid precursor protein (APP), a transmembrane protein consisting of 695-770
amino acids involved in neurodevelopment, synaptogenesis, and cell adhesion. APP is
proteolytically processed along two separate pathways: 1) the amyloidogenic, which
leads to amyloid-beta (Aβ) production, and 2) the non-amyloidogenic pathway (Moya
et al., 1994; H. Zhang et al., 2012). As illustrated in Fig. 1.1, in the non-amyloidogenic
pathway, APP cleavage is mediated by α-secretases (ADAM9, ADAM10, or ADAM17),
releasing the larger soluble ectodomain sAPPα. The membrane-anchored carboxyterminal domain of C83 can undergo further cleavage by γ- secretase to produce p3
(Pietri et al., 2013), an innocuous fragment. In the amyloidogenic pathway, βsecretase (BACE1) first cleaves APP to release an ectodomain (sAPPβ), leaving 99
amino acids of APP within the membrane (C99). C99 is then cleaved by γ-secretase 3843 amino acids from the N-terminus to produce Aβ (H. Zhang et al., 2012b). The final
cleavage of Aβ produces fragments that vary in length from 37-43 amino acids. The
longer Aβ peptides, including Aβ1-42, are more hydrophobic and more prone to
aggregate in the brains of AD patients. Low concentrations (pM) of Aβ1-42 have been
confirmed in the interstitial fluid of normal brains by micro-dialysis. However, higher
concentrations in the nM-μM range lead to neurotoxicity and neuronal death (Cirrito
et al., 2003).
1.2.2 Physiological Functions of APP Cleavage Products
Despite the intense focus in AD research on APP processing and amyloid peptides, the
normal functions of APP remain elusive. Apart from the brain, APP is also expressed in
other non-neuronal tissues and gives rise to Aβ outside the central nervous system.
The "Amyloid hypothesis" focuses on the imbalance of production and clearance of
5

Aβ1-42 and its related peptides as the neurotoxic factors that contribute to gradual
impaired neuronal function and cell death as seen in the progressive pathology of AD
(Selkoe & Hardy, 2016). Numerous therapies and studies have focused on
understanding both the physiological roles of APP and its cleavage products. They also
focus on how the imbalance of these products may contribute to neurodegeneration
to provide treatments that do not exacerbate the effects of depleting what could be a
necessary and functioning protein. For example, APP knockout (KO) mice initially
appear normal but eventually show reductions in body weight, grip strength,
locomotor activity, and synaptic transmission, as well as sensitivity to epileptic
seizures, forebrain defects, and a reduction in cerebral blood flow as a response to
ischemia (restriction in blood supply) or hypoxia (oxygen deprivation) (Koike et al.,
2012; Zheng et al., 1995). Intriguingly, APP KO mice show age-related deficits in
memory retention, suggesting that APP or its peptide derivatives may be required
during the development and maintenance of neuronal networks or may play a role in
long-term memory in the adult brain. (Dawson et al., 1999; L. Luo et al., 1992; Müller
et al., 1994; Seabrook et al., 1999; Senechal et al., 2008; Yu et al., 2001).
Moreover, antibody- or antisense-mediated blockade of APP disrupts learning
and memory (Doyle et al., 1990; Garcia-Osta & Alberini, 2009; G. Huber et al., 1993;
Mileusnic et al., 2005). Consistently, Aβ processing enzymes, such as the β site APP
cleaving enzyme 1 (BACE1), γ- and ε-secretases, are regulated by neuronal activity that
facilitates learning and memory and synaptic plasticity (Huifang et al., 2007; Kamenetz
et al., 2003; Laird et al., 2005a; Nitsch et al., 1992). On the other hand, mice
overexpressing human APP showed increased basal levels of double-stranded DNA
breaks (DSBs). Moreover, they retained this damage long after exploring novel
6

environments, implicating a reduced capacity for DNA repair through unknown
mechanisms (Suberbielle et al., 2013b). Although the memory stimulating
environment induces DSBs (Crowe et al., 2006; Madabhushi et al., 2015; Stott et al.,
2021), whether activity-dependent Aβ production plays a critical role in memory
formation remains unexplored. Supporting this observation, BACE-1 deficient mice
show altered synaptic plasticity and impaired cognitive and emotional abilities, and
inhibition of its activity negatively affects the long-term potentiation (Laird et al.,
2005b; Willem et al., 2015). Furthermore, adult hippocampal neurogenesis is
negatively affected in BACE1 knockout mice, suggesting it plays an essential role in
neuronal differentiation in the hippocampus, which is vital for learning and memory
(Chatila et al., 2018). Further emphasizing the above-mentioned critical aspects,
clinical trials using BACE1 inhibitors did not improve clinical dementia ratings and
worsened the cognition scores in some patients (Egan et al., 2019; Henley et al.,
2019a).
γ-secretase knockouts are not conducive to AD studies as this enzyme is not
specific to a single pathway. The γ-secretase complex cleaves numerous substrates,
including APP and Notch. Specifically, the γ-secretase subunit PSEN1 is a crucial
regulator of Notch and Wnt and is essential for glia and neurons' developmental
maturation. Notch signaling itself is responsible for neuronal differentiation during
embryogenesis and is also involved in neuronal plasticity (Louvi & Artavanis-Tsakonas,
2006). PSEN1 knockout mouse models exhibit perinatal lethality, skeletal
deformations, intracranial hemorrhaging, and CNS abnormalities resembling Notch
knockout phenotypes (Lathia et al., 2008; Shen et al., 1997). PSEN2 knockout mice
only show a mild pulmonary phenotype, indicating that the γ-secretase subunits
7

PSEN1 and PSEN2 have non-identical functions in mice (Donoviel et al., 1999;
Herreman et al., 1999). Conditional knockout of both PSEN1 and 2 in forebrain
neurons impaired memory, reduced synaptic plasticity and led to age-dependent
neurodegeneration (Feng et al., 2004a; Saura et al., 2004; C. Zhang et al., 2009a). The
double deletion of PSEN1 and 2 in mice is embryonic lethal, but an adulthood knockout
is viable and results in degeneration in the forebrain and enlargement of both
ventricles (Feng et al., 2004b). Numerous γ-secretase inhibitors have been tested to
reduce the amount of Aβ produced in mouse models and patients. These inhibitors
specifically target the PSEN1 and PSEN2 subunits of γ-secretase. However, due to offtarget effects and side effects, using these γ-secretase inhibitors in clinical trials is not
possible (Golde et al., 2013).
1.2.3 Evolving Concepts
Evidence supporting the amyloid cascade hypothesis includes, for instance, that
mutations in genes related to APP metabolism cause FAD (Munter et al., 2010).
Moreover, an extra copy of APP in Down's syndrome leads to plaques even in
adolescents with AD pathology, presumably due to overproduction of Aβ (Selkoe &
Hardy, 2016). Due to the popularity of the amyloid cascade hypothesis, principally, all
disease-modifying drugs in clinical trials have been aimed at altering the
concentrations of Aβ in the brain in different ways. However, so far, most of them
have failed.
While Aβ plays a central role in the progression of AD, emerging works suggest
that the causal effects may not be limited to Aβ alone. Moreover, it is also becoming
apparent that inhibiting endogenous Aβ production can cause neurotoxicity and
exacerbate memory impairment in human AD patients (Laird et al., 2005; C. Zhang et
8

al., 2009). The loss-of-function mutations in PSEN that decrease Aβ42 production led
to the 'presenilin hypothesis' of AD, stating that AD pathogenesis occurs due to a lossof-function state of γ-secretase (Shen & Kelleher, 2007). Another observation from
imaging studies in the elderly age groups and even in younger patients, the
accumulation of Aβ peptides does not correlate with cognitive performance.
There are a few other alternative hypotheses for the underlying cause of AD,
two of which focus on inflammation (Akiyama et al., 2000) and oxidative stress
(Markesbery, 1997). For a long time, it has been known that there is a
neuroinflammatory component to AD. However, the inflammation has most often
been assumed to be a consequence of, or response to, the pathophysiological changes
(Heppner et al., 2015). The inflammatory processes within the brain are driven by
microglia, and the degree of inflammation increases with disease progression
(Akiyama et al., 2000). Moreover, strong associations between AD and mutations in
several genes related to the immune system have been identified, and there are
reports of increases in inflammatory cytokines, chemokines, and other molecules
related to inflammation (Heppner et al., 2015). The other central alternative
hypothesis, oxidative stress, also has a lot of supporting evidence, including increased
DNA and protein oxidation in AD and studies showing that Aβ peptides can generate
free radicals (Markesbery, 1997). Oxidative damage occurs early in the disease
process, preceding a high plaque load, and has been linked to abnormal tau
phosphorylation and mitochondrial dysfunction (M. T. Lin & Beal, 2006).
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1.3 Additional Risk Factors
With the number of AD patients in the world increasing gradually and no definitive
cure or preventive treatment available, the identification and avoidance of modifiable
risk factors associated with the disease could help in reducing the disease burden. One
of the most decisive risk factors associated with cognitive decline is aging, with AD
prevalence around 19% for people ages 70-84 years and 30-55% for those older than
85 years (Ferri et al., 2005; Knopman, 2001). Apart from age, other risk factors include
traumatic brain injury, obesity, type 2 diabetes, and heart failure.
1.3.1 Vascular diseases
Vascular system alterations such as hypertension, atrial fibrillation, or cardiac arrest
reduce global cerebral perfusion and cause brain dysfunction and cognitive
impairment (Alosco et al., 2013; Iadecola, 2013). A history of hypertension in midlife
was associated with a 10% higher risk of developing AD later in life and a significant
increase in neuropathology (Gottesman et al., 2017). Thus, improvement in vascular
health and control of associated risk factors may reduce the risk for AD later.
1.3.2 Type 2 diabetes
95% of diabetes cases are type 2 diabetes and are characterized by hyperinsulinemia,
insulin resistance, impairment in glucose uptake, and pancreatic β-cell destruction. AD
is sometimes also described as type 3 diabetes, due to the epidemiological link
between type 2 diabetes and AD, with an increase in risk varying between 1.3 up to
5.5 times (Li et al., 2015). Imaging techniques have confirmed this dysregulation of
glucose metabolism alterations in the brain regions associated with AD pathology
before any evidence of cognitive decline (Nordberg et al., 2015).
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1.4 Diagnosis
AD diagnosis requires a comprehensive medical evaluation as there is no single test.
However, the National Institute on Aging-Alzheimer's Association has established
updated criteria to assess AD in the elderly, including a preclinical stage and degrees
of amyloid accumulation, tau tangle-bearing neurons, and neurite plaques (Hyman et
al., 2012). These criteria help to distinguish AD from other neurologic diseases such as
Parkinson's and Lewy body disease. There are scoring systems for determining the
extent, i.e. presence, distribution, and frequency, of plaques and NFTs. For example,
Braak stages (0-VI) determine the distribution of tau pathology (Braak & Braak, 1991).
In addition, there is the Consortium to Establish a Registry for AD (CERAD) neurite
plaque score, which is used to classify AD neuropathology into four groups (no or
negligible – high level) (Hyman et al., 2012).
There are several different tests aimed at assessing various aspects of cognitive
performance which can be used when evaluating suspected dementia in a patient. The
most widely used screening test for evaluating cognition is called Mini-Mental Status
Examination (MMSE) and was first described by Paul R. McHugh and colleagues in
1975, but it is still extensively used. The MMSE test comprises 30 points distributed
on 19 items measuring orientation, memory, concentration, language, and praxis.
Generally accepted cut-off scores are cognitively intact (27-30), mild AD (21-26), and
moderate AD (12-20). The Cognitive Abilities Screening Instrument (CASI) has a score
range of 0 to 100. It provides a quantitative assessment on concentration, orientation,
short-term memory, long-term memory, language abilities, attention, visual
construction, list-generating fluency, abstraction, and judgment (Liu et al., 2002). The
scoring in CASI varies from 0-100, with scores lower than 90 indicating possible mild
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cognitive impairment (L. Wang et al., 2004). However, it is not possible, or at the very
least very difficult, to discriminate between AD and other dementias solely based on
clinical history coupled with cognitive and neuropsychiatric tests, which is why
biomarkers are essential.
1.5 Major Pathways Affected in AD Brains
The hallmarks of AD include neuronal loss in some brain regions, with early affected
areas comprising the medial temporal lobe (hippocampus and entorhinal cortex) and
intraneuronal NFTs and extracellular neurite plaques. The NFTs consist of aggregated
and sometimes truncated hyperphosphorylated tau protein. At the same time, the
plaques are composed of Aβ peptides (Blennow et al., 2006), mainly ending at amino
acid (AA) 42, i.e. AβX-42 (Portelius et al., 2010). Plaques follow a general path of
spreading from cortical to subcortical regions (Thal et al., 2002), while NFTs spread in
an opposite pattern (Braak & del Tredici, 2015; Brettschneider et al., 2015). In the
more advanced stages of AD, the neuroanatomical distribution of NFTs correlates both
with the cognitive domains that are affected and areas of neuronal death (Nelson et
al., 2012).
However, only one type of neuropathological change is rarely present in an
elderly individual. Studies show that irrespective of clinical symptoms and diagnosis,
up to around 70% of cases display multiple pathologies, such as AD pathology, Lewy
body pathology, vascular pathologies, TAR DNA binding-protein 43 (TDP-43)
proteinopathy, and hippocampal sclerosis, and comorbidity of these pathological
changes has been shown to increase with age (Rahimi & Kovacs, 2014). Almost 40% of
dementia cases that are not clinically diagnosed as AD display enough AD
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neuropathology to fulfill the criteria for an AD diagnosis (Beach et al., 2012). It is also
worth noting that AD pathology is quite common in non-demented older individuals
(Braak & del Tredici, 2015), with studies estimating 30-40% of cognitively healthy
elderly individuals are classified as positive for AD pathological change upon autopsy
(Bennett et al., 2006; Knopman et al., 2003; Price et al., 1991).
1.5.1 Synaptic Loss
Dynamic modulation of the number and strength of synaptic connections in the brain
is fundamental to the formation and retention of memory in response to different
stimuli. Synapse is a unique cellular junction allowing contact between two neurons
that usually forms between a specialized ending (axon terminal) of a neuron
transmitting the information (the presynaptic neuron) and dendrites of a receiving
neuron (the postsynaptic neuron). Synapse is the site for electrochemical
communication between neurons (Bliss & Collingridge, 1993). The plasticity of the
neuronal synapse is defined as a stimulus-dependent increase or decrease in the
efficiency of synaptic transmission across the connection (Hebb, 2005; Kandel, 2001).
Synaptic dysfunction is a crucial feature of pathogenesis for dementia and
neurodegenerative diseases (Etherton et al., 2011; Hanson et al., 2007; Lepeta et al.,
2016). Change in synaptic efficacy, such as long-term potentiation (LTP) and long-term
depression (LTD), is widely accepted as the core basis for memory formation
(Andersen et al., 1977; Kumar, 2011). Synapse loss is the earliest marker in disease
pathogenesis that manifests in AD and MCI patients. Loss of synaptic connections
shows the best correlation, among neuropathological markers, to cognitive decline in
patients (DeKosky & Scheff, 1990; Scheff et al., 2006). This loss of synaptic contacts in
AD brains occurs earliest in the neocortex and hippocampus regions, associated with
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information processing and plasticity. Depletion of several neurotrophic factors, such
as BDNF (brain-derived neurotrophic factor), NGF (nerve growth factor), and VGF,
associated with synaptic modulation, is observed in AD brains (Cocco et al., 2010;
Ferrer et al., 1999). Although there is sufficient evidence regarding the role of synapse
loss in AD pathogenesis, the mechanism for this pathological loss in synapse numbers
is yet unknown. BDNF overexpression did not reduce the cognitive decline in AD
mouse models, and increased neurogenesis was required to get effective
improvement in disease pathology. However, it was still insufficient to slow the
cognitive decline (Choi et al., 2018).
1.5.2 DNA Damage Accumulation
Oxidative stress is characterized by an imbalance in the production of reactive oxygen
species (ROS). It manifests in high levels of oxidized proteins, advanced glycation end
products, lipid peroxidation end products, and the formation of toxic species such as
peroxides, alcohols, aldehydes, free carbonyls, ketones, and oxidative modifications
in nuclear and mitochondrial DNA. ROS are generated endogenously by cellular
metabolism and various exogenous agents such as ionizing radiation. Metabolically
generated ROS can generate ~10,000 oxidative lesions in DNA per day (Ames et al.,
1993). Neurons also have many mitochondria, which are the primary sources of ROS
during glutamate excitotoxicity, and impairment in mitochondrial function is
implicated in both aging and AD (D. Nguyen et al., 2011; Swerdlow, 2011).
Oxidative DNA lesions resulting from ROS can consist of single-strand DNA
breaks (SSBs) and DSBs and oxidized base adducts such as 8-hydroxyguanosine (8-oxodG). Studies have found increased levels of 8-oxo-dG in mitochondrial and nuclear
DNA in the cortex of AD patients and increased levels of γ-H2AX, a modified histone,
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and marker for DSBs, in the hippocampal region of AD patients (Mecocci et al., 1994).
This increase in DNA damage and mitochondrial dysfunction are observed in the
earliest stage of disease, with significant changes in the mild cognitive impairment
stage (MCI) (Cenini & Voos, 2019; Shanbhag et al., 2019a; Swerdlow, 2011a),
suggesting an essential role of increased DNA damage in early stages of pathogenesis
for AD.
DSBs and SSBs were detected at the DNA level in the hippocampus region of
AD patients (Adamec et al., 1999). The brain is highly vulnerable to impaired DNA
repair pathways due to higher metabolic and transcription activity in the central
nervous system (Canugovi et al., 2013). Physiological activity or stimulation in a novel
environment has been shown to cause DSBs. These breaks are localized to the
promoter regions of early response genes (Suberbielle et al., 2013a); these genes
function in learning and memory (West & Greenberg, 2011). DSBs are repaired by
either homologous recombination (HR) or non-homologous end-joining (NHEJ)
(Ceccaldi et al., 2016). BRCA1 plays an essential role in DSB repair using the HR process,
and recruitment of BRCA1 to DSBs commits cells to HR (Figure 1.2) (Ceccaldi et al.,
2016). The reductions in BRCA1's ability to manage DSB repair are suggested in AD
brains. Decreases in BRCA1 expression were detected in AD and MCI brains
(Suberbielle et al., 2015; Wezyk et al., 2018). Oxidized DNA damage is repaired by base
excision repair (BER) pathways. BER starts with recognizing and removing an oxidized
base by a DNA glycosylase, including 8-oxo-dG DNA glycosylase, OGG1 (Figure 1.2). A
decrease in the activity of OGG1 has been observed in the hippocampus and other
regions of AD patients compared to age-matched controls (Lovell et al., 2000). This
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impairment in BER was also observed in MCI patients and the mitochondrial lysates
from AD brains (Canugovi et al., 2014; Weissman et al., 2007).
1.5.3 Protein Synthesis Impairment
Protein synthesis in the neurons occurs majorly in the soma region. However, it has
been identified that the neuronal nerve endings, dendrites, and axons also carry out
protein synthesis (Giuditta et al., 2002; Sasaki, 2020a). This capability of neurons to
carry out local protein synthesis is required to support critical physiological functions,
such as regeneration, survival, and synaptogenesis (Miniaci et al., 2008; Sahoo et al.,
2018a). The synaptic modulation of protein synthesis correlates with learning ability
in rats and is also essential for releasing neurotransmitters in the mammalian brains
(Eyman et al., 2007, 2013; Younts et al., 2016). Recent works have indicated that local
protein synthesis alterations are associated with multiple neurological pathologies
(Costa & Willis, 2018). It has been reported that protein synthesis pathways,
specifically mTOR (mammalian target of rapamycin) dependent, are activated in AD
brains (An et al., 2003; Li et al., 2005; Oddo, 2012). Paradoxically, the brains of human
AD patients exhibit reduced protein synthesis capacity (Langstrom et al., 1989; Mann
et al., 1981; Sajdel-Sulkowska & Marotta, 1984) through yet unknown mechanisms.
The initiation step for translation is highly regulated and requires the
formation of a ternary complex on the mRNA. This complex consists of methionyltransfer RNA (Met-tRNA), guanine-triphosphate (GTP), and eukaryotic initiation factor
2 complex (eIF2) (Jackson et al., 2010). The guanine exchange factor (GEF), eIF2B,
allows ribosome assembly to initiate translation. This step is regulated by
phosphorylation of Ser51 of α subunit in the complex, eIF2α, which inhibits the GEF
activity of eIF2B and attenuates translation (Pavitt, 2018). Cellular stress and
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exogenous stimuli alter the global translation capacity of the cell by phosphorylation
of eIF2α, and this process is termed an integrated stress response (ISR). ISR facilitates
the translation of a subset of mRNAs to restore a homeostatic state (Kenner et al.,
2019). ISR makers are elevated in the AD patient's brains, and its inhibition rescues
some of the memory deficits in AD mouse models (Ma et al., 2013; RC et al., 2002).
ISR inhibitor (ISRIB), a small molecule that mitigates ISR, rescued protein synthesis in
AD mouse models with an increase in synaptic plasticity and cognitive abilities,
showing promise in targeting protein synthesis pathways to prevent the cognitive
decline in AD patients(M. M. Oliveira et al., 2021). However, this promising rescue for
cognitive abilities did not occur in other AD mouse models, and some adverse effects
have been reported (Briggs et al., 2017a; Johnson & Kang, 2016a).
The elongation step for translation requires amino-acylated tRNAs to be
delivered to the ribosome, facilitated by the eukaryotic elongation factor 1A (eEF1A)GTP complex. Following the release of eEF1A-GDP, the aminoacyl tRNA gets
accommodated in the A site of the ribosome subunit, and eEF1A-GDP is recycled to
eEF1A-GTP by the exchange factor eEF1B. Peptide bond formation is followed by the
transition of A and P site tRNAs into hybrid states and the acceptor tRNAs moving into
P and E sites, respectively. This translocation is tRNAs into P and E sites is facilitated
by eEF2-GTP, followed by the release of eEF2-GDP. Phosphorylation of eEF2 on Thr56
by its kinase eEF2K inhibits its binding to the ribosome, inhibiting de novo protein
synthesis (Carlberg et al., 1990). Interestingly, Aβ42, glutamate, and oxidative stress
induce the phosphorylation of eEF2 (Jan et al., 2017; Sanchez et al., 2019; Scheetz et
al., 1997). Moreover, the levels of p-eEF2 are upregulated during aging and in AD
mouse models, and the genetic knockdown of eEF2K attenuates the AD pathology in
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mouse models (Beckelman et al., 2019). Thus, pharmacologically targeting protein
synthesis capability for therapeutic interventions in AD patients is a possible avenue
that needs to be explored further.
1.6 Conclusion
This chapter briefly covers the current knowledge on Alzheimer’s disease, with aging
being the most-decisive risk factor, apart from other risk factors. Despite the
popularity of the amyloid cascade hypothesis, we discussed how all disease-modifying
drugs in clinical trials aiming at altering the concentrations of Aβ peptides or Aβ
plaques in the brain have failed. Furthermore, inhibition of Aβ production using small
molecules rather had detrimental effects on cognition scores over prolonged
treatment at higher doses (Henley et al., 2019b) along with neurotoxic effects (Chatila
et al., 2018; Laird et al., 2005b; Y. Luo et al., 2003). Although synapse loss is one of the
earliest markers for the disease, the molecular mechanisms that drive this effect are
not well-known.
This dissertation unravels that dysregulated brain protein synthesis and
accumulation of neuronal oxidative DNA damage are potential pathophysiological
pathways that can be targeted against Alzheimer’s disease using small molecules. This
dissertation is divided into several chapters.
Chapter 2 brings together the importance of regulating protein synthesis
pathways by memory-stimulating factors and the dysregulation of these pathways in
neurocognitive disorders. Our re-analysis of publicly available proteomics and
metabolomics data showed that serum tyrosine levels increase during aging and
neurological disorders, including AD. In tandem, bioinformatics analysis using
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transcriptomics and proteomic data from brain tissues showed that tyrosyl-tRNA
synthetase (TyrRS) is downregulated in affected brain regions of AD patients. Despite
having a positive correlation with cognition, TyrRS level doesn’t correlate with various
known neurodegenerative markers. We previously showed that resveratrol (RSV) is an
active site inhibitor for TyrRS and low-dose trans-RSV gets converted to cis-RSV in a
TyrRS-dependent manner. However, clinical trials using trans-RSV brought mixed
results with no explanation at the molecular level. Here we found that the two isomers
of resveratrol, cis-RSV and trans-RSV, bind to TyrRS in distinct conformations with cisRSV evoking a ‘tyrosine-free’ conformation and trans-RSV mimicking a ‘tyrosine-like’
conformation. This novel observation indicated that the two isomers of resveratrol
would evoke differential effects in vivo, providing a plausible explanation for the
controversial outcomes of resveratrol in clinical trials (Jhanji et al., 2021b).
Chapter 3 is a methods chapter covering all the techniques used in this
dissertation. In Chapter 4, we validated the decrease in TyrRS protein level in AD brains
using the hippocampal tissue samples and describes in detail our findings that tyrosine
itself is a potential causal agent that depletes neuronal TyrRS. In contrast, dopamine
– a neurotransmitter derived from tyrosine, stimulated de novo synthesis of TyrRS.
This chapter also details the mechanisms through which tyrosine depletes nuclear
TyrRS and induces neuronal oxidative DNA damage.
Chapter 5 addresses the differential effects of the two isomers of resveratrol
on TyrRS protein levels, neuronal DNA repair, and survival. This chapter describes the
molecular basis of trans-RSV-mediated depletion of TyrRS protein that results in
neuronal oxidative DNA damage. On the other hand, cis-RSV increases the TyrRS
protein level, facilitates DNA repair, and provides neuroprotection in a TyrRS19

dependent manner. These findings offer a plausible explanation for the high dose
trans-RSV-mediated detrimental effects in clinical trials and low-dose trans-RSVmediated the beneficial effects through its conversion to cis-RSV in vivo.

Figure 1.1 Amyloidogenic and non-amyloidogenic pathways for APP processing. APP
can be processed in two pathways: the amyloidogenic and non-amyloidogenic
pathways. In the non-amyloidogenic pathway, α-secretase cleaves APP in a way that
prevents the formation of amyloid-β (Aβ) peptides 40 and 42. It releases the APP Cterminal fragment 83 (C83) and soluble amyloid precursor protein α (sAPPα). C83 is
cleaved by γ-secretase to release the APP intracellular domain (AICD) and P3 fragment.
In the amyloidogenic pathway, in turn, β-secretase cleaves APP to release sAPPβ
(soluble amyloid precursor protein β), and the APP C-terminal fragment 99 (C99). C99
is later cleaved by γ-secretase, resulting in the release of Aβ peptides 40/42 and AICD.
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Figure 1.2 Simplified schematic for DNA repair pathways affected in Alzheimer’s
disease. Proteins in different DNA repair pathways are downregulated in AD brains at
activity levels or mRNA levels. The affected proteins in AD brains with reduced activity
are marked red with BRCA1 and RAD51 in HR, XRCC4 in NHEJ and OGG1, Polβ in BER
based on data reported in X. Lin et al. (2020). This figure has been adapted from a
template for DNA repair pathways in Biorender.
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Figure 1.3 Simplified schematic representation for the mechanism of regulation
initiation and elongation steps for protein synthesis. Protein synthesis is regulated at
the initiation and elongation steps by phosphorylation of eIF2α and eEF2. PP2A and
PP1 dephosphorylate eIF2α and eEF2 respectively, activating protein synthesis.
Dopamine and BDNF activate the mTOR pathway, thus inhibiting eEF2K to increase
protein synthesis at the elongation step.
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CHAPTER 2
ELEVATED TYROSINE IN AGING, NEUROCOGNITIVE AND METABOLIC DISORDERS
2.1 Role of de novo Protein Synthesis in Memory
The critical role of de novo protein synthesis in the formation and maintenance of
long-term memory has been known for a long time (Costa-Mattioli et al., 2009; J. B.
Flexner et al., 1963; P. J. Hernandez & Abel, 2008b). Later works showed that synapse
maintenance and activity-dependent modulation of synaptic strength depend on de
novo protein synthesis. The discovery of mRNA, ribosomes, and translation machinery
in dendrites and axons established that synapses could be modified directly and
perhaps individually through regulation of local protein synthesis (Sahoo et al., 2018b;
Sasaki, 2020b). Furthermore, both pre-synaptic and post-synaptic regions of the
synapse carry out activity-dependent de novo protein synthesis (Bramham & Wells,
2007; Holt et al., 2019).
The brain-derived neurotrophic factor (BDNF) is released at the synapse in an
activity-dependent manner and plays a vital role in regulating translation (Malcangio
& Lessmann, 2003). BDNF increases dendritic arborization, modulates synaptic
transmission, and plays an essential role in the regulation of local translation during
long-term potentiation (LTP) (Alsina et al., 2001; Kang & Schuman, 1996). Different
neurotransmitters such as dopamine, serotonin, and neurotrophic factors such as
BDNF, NGF are associated with the activity-dependent increase in de novo protein
synthesis at the synapse (Baj et al., 2016; Clos et al., 2019a; Eu et al., 2021).
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Several high throughput and single candidate approaches have been used to identify
the neuritic proteome and transcriptome (or locally translated). As a result, there are
approximately 2550 mRNAs known to be present in the neuritic fractions (Cajigas et
al., 2012). Locally synthesized proteins include the activity-regulated cytoskeletal
protein (Arc), the Ca++/calmodulin-dependent kinase IIR (CaMKIIR), and other
proteins known to play essential roles in the formation, maturation, and plasticity of
a synapse (Takei et al., 2001, 2009a). However, it is unknown whether the activitydependent increase in de novo protein synthesis is specific to certain mRNA species
and how it differs depending on the stimulus or the strength of the stimulus.
Moreover, the exact molecular mechanism and potential factors involved in altering
this protein synthesis capacity or selecting specific mRNAs for translation are
unknown.
2.1.1 BDNF Stimulates Memory
BDNF can exert highly localized effects on translation within dendrites and axons
(Bramham & Wells, 2007). Proteomic studies using rodent hippocampal neurons
showed that BDNF treatment increased the abundance of ribosomal proteins,
translation factors, possibly supporting an increased translation capacity at synapses
and contributing to the increased local translation in the consolidation phase of LTP
(Cajigas et al., 2012; Liao et al., 2007). BDNF decreases with aging and correlates with
age-associated cognitive decline. BDNF signaling and protein levels are decreased in
AD and Parkinson's Disease (PD) patients (B. Lu et al., 2013). Over-expression of BDNF
protects against neurotoxicity in animal models, and its exercise-induced expression
has been linked to improved cognition in AD patients (Arancibia et al., 2008; Ferrer et
al., 1999b). BDNF dependent increase in total synaptic protein expression is associated
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with an increase in expression levels and activity of eEF2, allowing more mRNAs to be
converted into proteins (Takei et al., 2009b). Other than elongation, the pathways for
mammalian target of rapamycin (mTOR) and eukaryotic initiation factor 4 E (eIF4E)
are also activated after BDNF treatment (Alsina et al., 2001; Takei et al., 2001). A
combination of both exercise and pharmacologic activation of BDNF signaling rescued
cognitive defects in AD mice (Choi et al., 2018b). However, currently, no single
therapeutic pathway can be effectively used to restore the loss of BDNF signaling in
AD patients.
2.1.2 Dopamine Signaling in Memory
Dopamine (DA) is the neurotransmitter associated with reward predictions,
motivation, and response to a stimulus. Dopaminergic signaling is also associated with
memory and synaptic modulation in the brain (Jay et al., 2004a). DA release in a novel
or enriched environment plays a vital role in learning and stimulation of dopamine
receptors dependent regulation of de novo protein synthesis is also associated with
local translation in neuron projections to maintain synapse (Mehta & Riedel, 2006).
DA and serotonin (5HT) dependent pathways are dysregulated in AD patients(Palmer
et al., 1987), with aging being a significant factor associated with the decline in levels
of DA and dopamine receptors (D1 and D2) (Clos et al., 2019b; Morgan, 1987).
Activation of the D1 dopamine receptor induces eEF2 pathway-dependent de novo
protein synthesis to increase the protein synthesis in the neurons (David et al., 2020).
Decreased DA activity in neurocognitive disorders such as AD and PD is attributed to
neurochemical alterations and neurodegeneration. The rate-limiting step in DA
synthesis is tyrosine hydroxylase (TH) activity, which catalyzes the formation of L-3,4dihydroxyphenylalanine (L-DOPA) from L-tyrosine. TH deficiency is linked to
25

behavioral and structural modification in the central nervous system (CNS), including
PD and schizophrenia (Dickson, 2018; Fioravanti et al., 2012). Despite having a central
role in memory, targeting the dopaminergic signaling using agonists, has not been
successful as a therapeutic strategy for AD due to its complex role in the modulation
of memory and cognition (Clos et al., 2018).
2.2 Protein Synthesis Dysregulation in Neurocognitive Disorders
Protein synthesis is dysregulated in many human diseases, including metabolic
disorders, immunodeficiency, neurological disorders, cancer, and viral infection.
Protein synthesis occurs in a tightly regulated manner to ensure the accurate
production of proteins in the proper location. It is especially critical for neuronal
survival and functioning due to its unique cellular architecture requiring spatiotemporal regulation. Thus, it is not unexpected that protein synthesis dysregulation is
implicated in many conditions, ranging from neurodevelopmental to neuropsychiatric
to neurodegenerative disorders. With advancements in proteomics and sequencing
techniques, increasing attention is focused on understanding the reasons for
disruption in translational regulation in the brain during the progression of various
neurological disorders. Autism spectrum disorder (ASD) is associated with mutations
in factors that regulate translation, specifically the initiation process and amino acid
transport. Additionally, new studies have highlighted the importance of translation
control in regulating neuropsychiatric disorders and mood disorders (Aguilar-Valles et
al., 2018; Takei et al., 2001). AD, PD and Huntington's disease (HD) all have activation
of the integrated stress response (ISR) and unfolded protein response (UPR), resulting
in a negative impact on neuronal functions (Hui et al., 2019). While the field focuses
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on dysregulation in translation at the initiation and elongation steps, mutations in
tRNAs and their charging or modifying enzymes are also associated with different
inherited recessive neurodegenerative disorders (Tahmasebi et al., 2018).
2.3 Aminoacyl-tRNA Synthetases in Neurological Diseases
Mutations of the cytosolic aaRSs were reported initially in peripheral neuropathies.
For example, autosomal dominant neuropathies have been associated with mutations
in AlaRS, HisRS, TyrRS, GlyRS, and TrpRS(Meyer-Schuman & Antonellis, 2017). In
addition, the autosomal recessive aaRS mutations have been recently reported in a
range of conditions often affecting the central nervous system, such as microcephaly,
epileptic encephalopathy, sensorineural hearing loss, developmental delay
(Boczonadi et al., 2018).
A recent proteomic study comparing the regional proteome of human AD
patients with age-matched control samples identified a reduction of aaRSs in AD
patients using mass spectrometry. The study identified 128 proteins to be affected in
five out of six brain regions analyzed in the postmortem tissue, hippocampus (HP),
entorhinal cortex (ENT), cingulate gyrus (CG), sensory cortex (SCx), motor cortex (MCx)
and cerebellum (CB). Among them, there were two cytoplasmic aaRSs, TyrRS, and
PheRSβ, and two mitochondrial aaRSs, IleRS2, and SerRS2(Xu et al., 2019), were
significantly decreased in AD brains (Figure 2.1). This decrease in aaRSs in AD brains is
consistent with the early studies reporting impairment in protein synthesis as an early
event in AD pathogenesis (Langstrom et al., 1989).
Another consensus proteomic study using the dorsolateral frontal lobe region
from AD patients aimed at identifying correlations between proteome and disease
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parameters showed that TyrRS and PheRSβ protein levels correlated positively with
cognitive results and negatively with disease severity (Figure 2.2). Moreover, though
the depletion of PheRSβ correlated with molecular markers for neurodegeneration,
TyrRS did not (Johnson et al., 2020). Moreover, the decrease in TyrRS protein in
different regions of human AD brains correlated with the pathogenesis of the disease,
with highly affected regions, hippocampus and entorhinal cortex, having higher
depletion than the less-affected regions.
Intriguingly, the molecular markers of neurodegeneration for plaques (Aβ) and
tangles (TauMTBR) correlate with a decrease PheRSβ, but not TyrRS protein. Apart
from the modulation of aaRSs with AD progression, ribosome occupancy (or
translation efficiency) for PheRSβ declines with aging in mice (Figure 2.3), while TyrRS
is not affected.
2.4 Amino Acids Regulation in Aging-related Diseases
Amino acids (AA) are key cellular metabolism and signaling regulators, apart from
being the building blocks for proteins. Lifespan extension of various organisms has
been associated with a calorie restriction (CR) diet resulting in a decrease in amino
acid intake, decreasing protein synthesis, and increasing proteostasis (Edwards et al.,
2015). Meanwhile, an imbalance of AAs can activate stress response machinery in the
cells. The presence of uncharged tRNAs in the cell is detected by general amino acid
control non-derepressible 2 (GCN2), an eIF2α kinase, resulting in activation of ISR and
a decrease in global protein synthesis, allowing cells to adapt to varying levels of AAs
(Gallinetti et al., 2013). An increase in AAs from two families is generally implied in
metabolic disorders such as diabetes, obesity, and cardiovascular diseases: BCAAs
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(valine, leucine, isoleucine) and aromatic amino acids (tyrosine, phenylalanine) (Tillin
et al., 2015; Wang et al., 2011). Plasma amino acid concentrations also vary with sex
and age, with higher concentrations in adult males compared to women and
increasing concentrations with aging (Andraos et al., 2021). Pro-aging effects are also
observed with some AAs (serine, threonine, and valine) in yeast (Mirisola et al., 2014).
An increase in different AAs is observed in many metabolic disorders and neurological
diseases (Table 2.1). Global metabolic disorders such as type 2 diabetes, obesity, and
cardiovascular diseases are associated with increased risk for AD. Thus, alterations of
AAs play a crucial role in altering regional metabolism and energetics, resulting in
pathogenesis in the form of cognitive impairment.
2.5 Elevated Tyrosine levels in Aging and Neurodegenerative Disorders
Tyrosine (Tyr) is a non-essential AA and can be synthesized from phenylalanine (Phe)
by the phenylalanine hydroxylase. Tyr is also a precursor for neurotransmitters
dopamine and norepinephrine. Activities of TH, tyrosine aminotransferase (Fishman
et al., 1969; Mcgeer & Mcgeer, 1966) regulate serum Tyr. Tyr plasma concentration
increases during human aging (Chak et al., 2019) and in human AD brain tissues (Huo
et al., 2020; Storga et al., 1996a). There is no sex difference in Tyr levels in children or
AD patients, but young women have lower serum Tyr levels than young men (Andraos
et al., 2021). However, menopause increases Tyr levels (Auro et al., 2014), resulting in
a significant increase in Tyr levels in older women from ~60-70 years (Table 2.2 and
Figure 2.4). Tyr and Phe are increased during delirium, heart failure (HF), Parkinson's
Disease (PD), autism spectrum disorders (ASD), cardiovascular diseases (CVD), and
other metabolic disorders in humans (Table 2.1). Genetic mutations that increase the
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levels of Tyr (tyrosinemia) or its precursor Phe [phenylketonuria (PKU)] cause multiple
health problems, including cognitive deficits in children (Huhn et al., 1998; Streck et
al., 2017). In one clinical study, dietary supplementation of Tyr was linked to an
increase in cognitive performance, but in another study in older adults exacerbated
cognitive decline (Bloemendaal et al., 2018; Rest et al., 2017). Increased plasma Tyr is
a biomarker for developing type 2 diabetes (T2D) in humans, a major risk factor for
dementia and AD.
Interestingly, an increase in Tyr and Phe levels inhibit aminoacyl-tRNA
synthesis in the brain ex vivo and inhibit protein synthesis (Lindroos & Oja, 1971).
Furthermore, Tyr induces DNA damage and promotes oxidative stress in the brain in
vivo in rats (de Prá et al., 2014; Sgaravatti et al., 2008). In a metabolomics study using
C57BL/6 mice, Tyr synthesis was found to negatively correlate with hypothalamic
transcript levels of Drd5, a dopamine receptor expressed in the limbic regions of the
brain that activates memory formation (Shivarama Shetty et al., 2016) and inhibits
tumor growth through autophagy induction (Leng et al., 2017). In addition to this,
calorie restriction (CR) significantly downregulates tyrosine biosynthesis and serum
tyrosine levels in mice (Green et al., 2019) as well as in humans (Zou et al., 2020).
2.6 Moonlighting Functions of TyrRS
Recent work on aaRSs has highlighted their functions beyond protein synthesis or nontranslational 'moonlighting' functions in various cellular pathways associated with
stress response (Guo et al., 2010). However, the molecular mechanisms for 'switching
ON' their 'moonlighting' functions are not well understood. Interestingly, the
depletion of tryptophan (Trp) from the active site of tryptophanyl-tRNA synthetase
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(TrpRS) activates its "moonlighting" nuclear function poly-ADP-ribose-polymerase 1
(PARP1)-dependent activation of p53 (Sajish et al., 2012).
2.6.1 Genetic Diseases Associated with TyrRS Mutations
Four missense mutations in TyrRS (G41R, E196K, D81I, E196Q) and one four AA
deletion (153_156del) in its catalytic domain are associated with dominantly inherited
Charcot-Marie-Tooth (CMT) neuropathy. CMT is a common peripheral neuropathy
associated with the degeneration of motor neurons (Jordanova et al., 2006; Mathis et
al., 2015; Niehues et al., 2015). A multi-system disease characterized by
developmental delay, liver dysfunction, and abnormal cortical white matter was found
to associate with autosomal recessive mutations (P213L, F269S, and G525R) in the
catalytic and C-domain regions of TyrRS, suggesting an unknown function in the
central nervous system (Cao et al., 2017b; Tracewska-Siemiątkowska et al., 2017). The
pathologies associated with TyrRS are not necessarily related to loss of function or
reduced efficiency in its translation function(Blocquel et al., 2017).
2.6.2 Nuclear Functions of TyrRS
Oxidative stress induces nuclear localization of TyrRS to protect against oxidative DNA
damage (Cao et al., 2017b; Wei et al., 2014). An over-expression of TyrRS protected
against UV-induced DNA damage in zebrafish, and restricting its nuclear translocation
exacerbated the beneficial effects (Cao et al., 2017a). The nuclear translocation of
TyrRS was increased after the knockdown of its cognate tRNA, indicating that this
translocation coordinates with the cellular protein synthesis demand (Fu et al., 2012).
Increased nuclear localization of CMT mutants of TyrRS in Drosophila melanogaster
was associated with sweeping changes in the transcriptome profile indicating a role in
transcriptional regulation (Bervoets et al., 2019).
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Interestingly, nuclear localization of TyrRS after either serum starvation, heat shock,
or endoplasmic reticulum (ER) stress stimulates the auto-poly-ADP-ribosylation of
(auto-PARylation) of PARP1, suggesting that eukaryotic TyrRS activates PARP1 in a
DNA-independent manner (Sajish & Schimmel, 2014) to facilitate TyrRS-mediated
DNA repair (Cao et al., 2017c; Gao et al., 2019b). However, TyrRS-regulated autoPARylation of PARP1 was lost in the presence of broken DNA, suggesting that factors
that induce DNA damage would abolish TyrRS/PARP1-mediated protective stress
response (Sajish & Schimmel, 2015).
2.7 cis-RSV Competes with Tyr and Binds to TyrRS
Increased levels of Tyr are associated with the etiology of various metabolic diseases
(Table 2.1) and resveratrol (RSV), a polyphenol secreted by plants in response to stress
acts as an 'active site-directed inhibitor' of TyrRS (Sajish & Schimmel, 2015).
Intriguingly, the crystal structure of TyrRS showed binding with only the cis-isomer of
RSV, unlike other known biological targets of RSV (F0/F1 ATPase, estrogen receptor
alpha [ERα], silent mating type information regulation 2 homolog 3 [SIRT3]) that bind
to the trans-isomer of RSV (Gledhill et al., 2007; G. T. T. Nguyen et al., 2013;
Nwachukwu et al., 2014). Therefore, TyrRS is the first and, so far, the only biological
target that binds to the cis-isomer of RSV. Interestingly, our recent analysis of the
structural determinants between cis-RSV bound TyrRS and its tyrosine-free (apo) form
demonstrated that cis-RSV mimics a tyrosine-free "apo” form (Jhanji et al., 2021b;
Sajish & Schimmel, 2014). Most significantly, RSV potentiated TyrRS-mediated autoPARylation of PARP1 in vitro at nanomolar (nM) levels with a half-maximal effect (EC50)
at roughly 10 nM, indicating that TyrRS/PARP1 complex is the biological target of RSV
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rather than TyrRS by itself. TyrRS-cis-RSV-PARP1-driven NAD+ signaling thus
upregulated the expression and activation of a battery of genes, proteins, and
signaling cascades that elicit a protective stress response.
However, in silico modeling of the active site of TyrRS with trans-RSV showed
that trans-RSV bound TyrRS would retain its Tyr bound conformation. Instead, this
retention of conformation would prevent the interaction and activation of PARP1
mediated through the conformational change, resulting in the opposite effect on
stress response and DNA repair. This observation that cis- and trans-RSV induce
distinct conformations in TyrRS with opposite effects on PARP1-dependent protective
stress signaling would potentially provide a molecular basis for the dichotomous
effects of RSV in various clinical studies with low-dose beneficial effects and higher
dose exacerbation (Jhanji et al., 2021b).
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Figure 2.1 aaRSs are depleted in affected regions of human AD brains. Changes in
protein levels of TyrRS (a), PheRSβ (b), IleRS2 (c) and SerRS2 (d) from six functionally
distinct regions of human post-mortem brain of AD cases versus asymptomatic
controls: entorhinal cortex (ERC), hippocampus (Hip), cingulate gyrus (CG), sensory
cortex (SCx), the motor cortex (MCx) and cerebellum (CER) identified using mass
spectrometry. Proteins with a false discovery rate (FDR) ≤ 5% were significant. These
graphs were created after re-analyzing data published in Xu et al. (2019).
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Figure 2.2 Brain protein levels of TyrRS and PheRSβ correlate with human cognitive
performance and dementia. Biweight midcorrelation (BICOR) coefficient of TyrRS and
PheRSβ were created using data published by Johnson et al. (2020). Brain TyrRS and
PheRSβ levels positively correlate with human cognitive function (a), and negatively
correlated with AD case status and disease severity (b).

35

Figure 2.3 TyrRS does not correlate with markers for neurodegenerative diseases. a.
Age-dependent decline in ribosome occupancy of PheRSβ in mouse liver. Graph created
by re-analyzing published data from Anisimova, A. S. et al. Mouse livers representing
six age groups (1-, 3-, 11-, 20-, 26-, and 32-month-old) were used. The dynamics of
age-related changes in ribosomal coverage of mRNAs were assessed by obtaining a list
of nonoverlapping segments with stable footprint coverage and normalized to the
mean coverage at three months. b. Brain TyrRS levels do not correlate with known
neurodegenerative disease markers. The BICOR coefficient of PheRSβ correlates with
known molecular markers of neurodegenerative diseases. Biweight midcorrelation
(BICOR) coefficients for TyrRS and PheRSβ are reported using data published by
Johnson et al. (2020).

36

Figure 2.4 A model of age-dependent increase in serum tyrosine concentrations. The
model graph was built using data obtained from different longitudinal metabolomic
studies assessing the effect of aging on metabolic profiles and their study
demographics mentioned in Table 2.2.

37

Figure 2.5 cis-RSV bound TyrRS mimics ‘Tyr-free’ (apo) conformation of TyrRS.
a. cis-RSV bound structure of TyrRS (PDB:4Q93). b. Superimposition of cis-RSV bound
and ‘apo’ form of TyrRS depicting similar structural conformation.
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Table 2.1 Elevation in amino acids is associated with age-dependent disorders
Condition/Disease
Elevated Amino Acids
References
Chak, CM, et al. 2019
Darst BF, et al. 2019
Hwangbo, N. et al. 2021
Andraos, et al. 2021
Tyr, Val, Gly, Leu, Ile,
Aging
van de Rest, O., et al. 2017
Gln
Ravaglia, G. et al. 2002
Kochhar, S. et al. 2006
Kouchiwa, T. et al. 2012
Rist, M. J. et al. 2017
Menopause
Tyr, Val, Glu, Ile, Gly
Auro, K. et al. 2014
Tyr, Phe, Trp, Ile, Thr,
Grant, L. K. et al. 2019
Sleep Deprivation
Pro, Lys
Gehrman, P. et al. 2018
Pandharipande, P. P. et al.
Tyr, Trp
Delirium
2009
Tyr, Phe, Trp
Watne, L. O. et al. 2016
Tyr, Phe, Trp, Asp, Thr,
Storga, D., et al. 1996
Alzheimer's Disease
Glu, Gln, Met, His, Pro,
Fekkes, D. et al. 1998
(AD)
Val and Ala (elevated in Kim, Y. H. et al. 2019
and
brain of AD patients)
Huo, Z. et al. 2020
Mild Cognitive
Tyr, Phe (plasma for
Ravaglia, G. et al. 2004
Impairment (MCI)
MCI)
Ravaglia, G. et al. 2002
Jimenez-Jimenez, F. J. et al.
2020
Parkinson's Disease
Vascellari, S. et al. 2020
Tyr, Phe
(PD)
Zhao, H. et al. 2018
Wu, J.F. et al. 2016
T. Hatano, et al. 2016
Tyr, Phe, Glu, Asn, Ala,
Skalny, A. V. et al. 2020
Autism Spectrum
Lys, Arg, Cys, His, Met,
Zou, M. Y. et al. 2020
Disorders (ASD)
Ser, Val
Aldred, S. et al. 2003
Traumatic brain injury
Vuille-Dit-Bille, et al. 2012
Tyr, Phe
(TBI)
Tyrosinemia I
Tyr
Bendadi, F. et al. 2014
Tyrosinemia II
Tyr
R. Huhn, H. et al. 1998
Tyrosinemia III
Tyr
Ellaway, C. J. et al. 2001
Phenylketonuria (PKU) Phe
Blau, N., et al. 2010
Felig, P., et al. 1969
Newgard, C. B., et al. 2009
Diabetes,
Wang, T. J. et al. 2011
Obesity, and Insulin
Tyr, Phe, Leu, Ile, Val
R. Yang, et al. 2014
Resistance
P. Wurtz, et al. 2014
Hellmuth et al, 2016
Cardiovascular Disease
Wurtz, P. et al. 2015
Tyr, Phe
(CVD)
P. Welsh, et al. 2018
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Hypertension

Tyr, Phe, Leu, Ile, Val

Myocardial IschemiaReperfusion injury

Tyr, Phe

Heart failure

Tyr, Phe Met, His

Stroke

Phe, His

Liver Diseases
(Cirrhosis
Hepatitis)

Tyr, Phe, Trp

Auto-Immune
Disorders

Tyr, Phe

Sepsis

Tyr, Phe, Cys, Met, Ala,
Asp, Glu, Pro
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Altorf-van der Kuil, W. et al.
2013
F. Teymoori, et al. 2018
A. Surendran, et al. 2019
Stryeck, S. et al. 2019
Murashige, D. et al. 2020
Hakuno, D., et al. 2015
Cheng, M. L. et al. 2015
Vojinovic, D. et al. 2020
S. J. O'Keefe, et al. 1981
C. H. Dejong, et al. 2007
M. Y. Morgan, et al. 1982
A. J. McCullough, et al.
1981
D. Blackmore, L. Li, et al.
2020
H. R. Freund, et al. 1978
H. Freund, et al. 1979

Table 2.2 Age-dependent changes in plasma tyrosine
Plasma Tyrosine
Age (mean)
concentration
64.1 ± 15.1 μM
46.2 ± 6.4 (n = 174, M)
59.8 ± 16.8 μM
43.6 ± 4.8 (n = 1150, F)
61 (54-70) μM
52 (47-61) μM
63 (55-69) μM
59 (50-75) μM
66.48 ± 17.29 μM
78.4 ± 15.24 μM
72.59 ± 17.04 μM
81.7± 17.69 μM

26 ± 4 (n = 68, M)
25 ± 5 (n = 72, F)
71 ± 7 (n = 32, M)
72 ± 8 (n = 42, F)
62.71(55-74, n = 317, F)
69.71 (62-81, n = 317, F)
62.69 (55-74, n = 273, M)
69.69 (62-81, n = 273, M)
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Reference
Andraos, et al., 2021
Caballero, et al., 1991

Chak, et al., 2019

CHAPTER 3
MATERIALS AND METHODS
3.1 Postmortem Hippocampal Tissue Samples
All human postmortem tissues were obtained from the University of Washington
School of Medicine BioRepository and Integrated Neuropathology (BRaIN) Laboratory
and Precision Neuropathology Core. AD diagnosis was based on cognitive assessments
of dementia and neuropathological verification of AD neuropathologic change using
Braak staging (AD stages V–VI) stage and Consortium to Establish a Registry for
Alzheimer’s Disease (CERAD) scores. Studies were performed using flash-frozen
hippocampal tissue from male and female patients clinically diagnosed with AD (n = 7)
and age-matched controls (n = 7). Donor information is presented in Table 3.1. The
mean age of death was 89.6 years. Postmortem interval (PMI) ranged between 2 and
11 hours, with a mean of 5.3 hours.
3.2 Animals
All mice were housed at the Wake Forest School of Medicine barrier facility under the
supervision of the Animal Research Program. Mice adhered to a 12-hour light/12-hour
dark cycle, with regular feeding, cage cleaning, and 24-hour food and water access.
WT and eEF2K+/–mice tissue samples (age 6 to 9 months) were obtained from a
previous study (Beckelman et al., 2019).
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3.3 Primary Neuronal Culture
Primary cortical neurons were dissected from E18 Sprague Dawley rat pups in
Hibernate E (BrainBits) and dissociated using the Neural Tissue Dissociation kit
(Miltenyi Biotec). Minced cortices were incubated in a pre-warmed enzyme mix at
37 °C for 15 min; tissues were then triturated and strained using a 40 µm cell strainer.
After washing and centrifugation, neurons were seeded in 50 µg/ml poly-D-Lysine
(Sigma Aldrich) coated tissue culture plates. NBActive-1 medium (BrainBits)
supplemented with 100 U/ml of Penicillin-Streptomycin (Life Technologies), 2 mM LGlutamine (Life Technologies), and 1 X N21 supplement (R&D Systems) was used as a
culture medium. Control (non-targeting), TyrRS, and PARP1 siRNAs were obtained
from Invitrogen (#AM4635, s443, and s130207, respectively). Rat cortical neurons at
DIV 5 were transfected with 75 nM control or TyrRS siRNA using Dharmafect 3
Transfection Reagent. Two days later, DIV 7, a second transfection, was done using
75nM of TyrRS siRNA, followed by cell collection or assays after another 48 hrs. For
PARP1 siRNA, neurons at DIV 7 were transfected with 75nM siRNA for both control
and PARP1 siRNA.
3.4 Western Blotting
Cultured neurons (DIV 9-10) were washed once with cold 1× PBS and lysed in cell lysis
buffer (20 mM Tris-HCl (pH 7.5), 150 mM NaCl, 1 mM Na2EDTA, 1 mM EGTA, 1% Triton,
2.5 mM sodium pyrophosphate, 1 mM beta-glycerophosphate, 1 mM Na3VO4, 1 µg/ml
leupeptin supplemented with protease inhibitor). The lysates were centrifuged at
10,000 RPM for 15 mins at 4°C to separate the chromatin-bound and soluble fractions.
Lysates were quantified using Bio-Rad Protein Assay, and equal amounts of protein
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were loaded onto a 4 to 12% gradient gel (NuPAGE-Invitrogen). Protein was
transferred from the gel to 0.2 μm NC membranes at 25 V for 10 mins using transfer
stacks (iBlot 2- Invitrogen) and blocked with 5% non-fat milk in TBST (10 mM Tris-HCl
pH 8.0, 150 mM NaCl, 0.01% Tween-20) for 1 hr before application of primary
antibodies. Primary antibodies were diluted to the required concentrations using 5%
BSA (BP9700100, Fisher Scientific) in TBST (Table 3.2). Primary and secondary
antibodies were incubated overnight at 4 °C and for 1 hr at room temperature,
respectively. Immobilon ECL Ultra Western HRP Substrate (WBULS0500, Millipore)
and a luminescent image analyzer (ChemiDoc Imaging System, Bio-Rad) were used to
detect proteins. Quantification of western blots was done using ImageJ (Version
1.53c).
3.5 Immunofluorescence (IF)
Cultured cortical neurons (DIV 9-10) were fixed in 4% formaldehyde for 15 mins,
followed by permeabilization and blocking for 30 mins in 5% BSA (PBS) and 0.1%
(Tween20) at room temperature. Incubation with primary antibodies was done at 4°C
overnight. The names and dilutions of the primary antibodies used for IF are listed in
Table 3.3. Secondary antibodies were incubated for 1 hr at room temperature.
Secondary antibodies used were: Alexa Fluor 647 (anti-chicken), Alexa Fluor 555 (antimouse), Alexa Fluor 488 (anti-rabbit) from Invitrogen at 1:1000 dilution. Coverslips
were then mounted using DAPI (4',6-diamidino-2-phenylindole)-supplemented
mounting medium, Prolong Gold Antifade (Invitrogen) and imaged with Leica
DMI6000 epifluorescent microscope using oil immersion 63x/NA 1.4 objective. The
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quantification for total protein levels in neurons was done using ImageJ (Version
1.53c), and imaging parameters were matched for exposure, gain, and offset.
3.6 Cell Viability Assays
Rat cortical neurons (DIV 10-11) were exposed to different treatments (NMDA, ETO,
H2O2, MPP+) after seeding 20,000 cells/well in 96-well plates. Cell viability was then
assessed 48 hrs after the initial exposure to NMDA. 3-[4,5-dimethylthiazole-2-yl]-2,5diphenyltetrazolium bromide (MTT) assays were used to assess change in cell viability.
Rat cortical neurons (DIV 9) were exposed to 5 µM etoposide (ETO, 28435 Chem
Implex), 400 µM H2O2 (H1009, Sigma Aldrich) or 10 µM MPP+ (D048, Sigma Aldrich) for
24 hrs after pre-treatment with cis-RSV or trans-RSV (50 µM) for 16 hr. Cultured rat
cortical neurons were incubated with MTT (0.5 mg/mL). In the MTT assay, after 2 hr
incubation, the insoluble purple product formazan resulting from the reduction of
MTT by NAD(P)H-dependent oxidoreductases present in cells with viable
mitochondria was solubilized in dimethyl sulfoxide at room temperature, under
agitation, and protected from light. The percentage of MTT reduced as measured by
the difference between the absorbances at 570 nm read in a spectrophotometer
(Spectramax 190R Molecular Devices, UK). Results are presented as a percentage of
control (wells incubated with the vehicle).
3.7 DNA Fiber Analysis
Cultured cortical neurons (DIV9) were treated with cis- and trans-RSV (50 µM) for 8
hrs, followed by the addition of thymidine analog, 50µM CldU (5-Chloro-2'deoxyuridine) for 30 mins. DNA fiber analysis was done according to established
protocols. Briefly, cells were isolated by trypsinization, embedded in agarose plugs,
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and subjected to proteinase K (0.5% SDS, 0.1 M EDTA, 1 mg/ml Proteinase K) digestion
at 50°C for 16 hr. Plugs were dissolved with agarose (Fisher [NEB], 50-811-726) for 16
hrs. Molecular combing was performed using the FiberComb® Molecular Combing
System (Genomic Vision) with a constant stretching factor of 2 kb/μm using vinylsilane
coverslips (20 × 20mm; Genomic Vision), according to the manufacturer’s instructions.
Combed coverslips were incubated at 60C for 2 hrs in a pre-warmed hybridization
oven to minimize photo-breaking, followed by denaturation of the DNA fibers (0.5M
NaOH + 1M NaCl) for 8 mins. The coverslips were washed with PBS, followed by serial
ethanol dehydration (70–100%). Following two 1x PBS washes, the coverslips were
blocked in 3% BSA/1x PBS for 30 mins, followed by incubation with α-BrdU (for CldU)
(BD [347,580]) (1:100) and ssDNA antibody (Millipore MAB3034) (1:100), for 2 hrs at
37°C. After three PBST washes, secondary antibody incubation was done using αmouse AlexaFluor 594 and α-rat AlexaFluor 488 (1:500) for 1 hr at 37°C. Coverslips
were washed three times with 1x PBST, dehydrated, and mounted on slides with
mounting media. The stained DNA fibers were visualized using a fluorescence
microscope (EVOS FL, ThermoFisher Scientific). Analysis was performed in ImageJ by
counting the total ssDNA (red), and the CldU labeled fibers (green). 300 fibers were
counted for each treatment condition. The average ratio of CldU incorporation for
ssDNA fibers per condition was used for final representation.
3.8 Neurite Degeneration Index
The neurite degeneration index was calculated as described previously (D. E.
Hernandez et al., 2018; Jin et al., 2011). Samples were imaged using ImageXpress
Micro 4 at a magnification of 10x to capture the entire field of interest. The samples
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analyzed

for

neurite

degeneration

were

stained

using

the

standard

immunofluorescence procedure with MAP2 (Alexa fluor 647) for neurites and DAPI
staining for the nucleus. Neurite degeneration was quantified using 5-6 regions of
interest of equal sizes from each treatment condition. The analysis of neurite
degeneration was done using ImageJ. The fluorescent images for MAP2 staining were
binarized so that the pixel intensity of regions corresponding to neurite staining was
converted to black, and all other regions were converted to white. Healthy intact
neurites show a continuous tract, whereas degenerated axons have a particulate
structure due to fragmentation or beading. To detect degenerated neurites, we used
the particle analyzer module of ImageJ. We calculated the percentage of the area of
the small fragments or particles (size = 3–10µm2) to the intact neurites (size > 25µm2)
with information derived from the binary images. A degeneration index (DI) was
calculated as the fragmented neurite area ratio over the intact neurite area.
3.9 Pharmacological Treatments
All stock solutions (1000x) for pharmacological treatments were prepared in DMSO or
ethanol and diluted in culture media for final concentration. cis-RSV was purchased
from Cayman Chemicals (Item No. 10004235, ≥ 98% purity) and trans-RSV was
purchased from Millipore-Sigma (catalog No. 34092, ≥ 99% purity) and the stocks were
prepared in ethanol. The various compounds used for treatments and their stock
concentrations are listed in Table 3.4.
3.10 SUnSET Assay
Puromycin (Sigma; P8833) is an aminonucleoside antibiotic produced by Streptomyces
alboniger. It is a widely used protein synthesis inhibitor. The structure of puromycin is
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analogous to tRNA, and it gets incorporated into nascent polypeptide chains, resulting
in inhibition of elongation of amino acids and thus translation. An assay termed
surface sensing of translation (SUnSET) was developed (Schmidt et al., 2009) that uses
puromycin as an indicator of the rate of protein synthesis in a cell. This approach can
be utilized the determine the effect of pharmacological treatment on the rate of
protein synthesis by adding puromycin just before the end of the treatment to allow
for its incorporation into nascent polypeptide chains. Subsequently, an antibody
against puromycin can be used to detect its incorporation post lysis. Puromycin
(10µM) was added in the last 15 minutes of the pharmacological treatment on rat
cortical neurons (DIV 8). The samples were lysed, followed by western blotting. The
puromycin incorporation was visualized using a puromycin antibody (MABE343, Sigma
Aldrich).
3.11 Comet Assay
Culture neurons (DIV 9) were treated with cis- or trans-RSV (50 µM) in combination
with tyrosine (1 mM) for 1 hour. Cells were harvested with a cell scraped using chilled
PBS followed by counting. The comet assay kit (Trevigen Inc, Gaithersburg, MD) was
used according to the manufacturer’s protocol using alkaline conditions.
Electrophoresis was carried out at the rate of 1.0 V/cm for 20 minutes. The slides were
removed from the electrophoresis chamber, washed twice in deionized water for 5
minutes, and immersed in 70% ethanol for 5 minutes. Subsequently, the slides were
dried at 37°C, DNA was stained with 50 µl of SYBR Gold dye (Fisher Scientific, 1:10000
in Tris-EDTA buffer, pH 7.5) for 20 minutes in the dark at room temperature. The
images were then analyzed using an epifluorescent microscope at 10X magnification
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and scored for comet parameters, such as tail length and moment (product of % DNA
in the tail and tail length) using the Tritek CometScoreTM Freeware v1.5 image analysis
software.

Table 3.1 Patient demographics for hippocampal tissue samples
Diagnosis

Sex

Age

PMI

ApoE

Braak
Stage

No dementia
No dementia
No dementia
No dementia
No dementia
No dementia
No dementia
AD
AD
AD
AD
AD
AD
AD

F
M
F
F
M
M
F
M
M
F
F
M
M
F

92
86
95
92
78
86
91
88
91
96
98
88
91
90

06:00
03:15
03:05
06:00
06:00
03:15
11:00
04:40
07:00
04:45
02:30
04:40
07:00
03:51

3/3
3/3
3/4
3/3
3/3
3/3
4/3
4/3
3/4
3/3
3/3
4/3
3/4
3/3

III
III
III
III
II
III
III
VI
V
VI
IV
VI
V
V

CERAD
Score
Rare
Absent
Absent
Rare
Sparse
Absent
Absent
Moderate
Moderate
Frequent
Frequent
Moderate
Moderate
Frequent

PMI: post-mortem interval; ApoE: Apolipoprotein E allele status; M: Male; F: Female
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Table 3.2 List of antibodies used for western blotting
Antibody
Company

Catalog No.

Dilution

Acetyl-Histone H3 (Lys56) Cell Signaling Technology

4243

1:1000 (WB)

Acetyl-Histone H3 (Lys9) Cell Signaling Technology

9649

1:1000 (WB)

ARH3

Proteintech

16504-1-AP

1:1000 (WB)

eEF2

Cell Signaling Technology

2332

1:1000 (WB)

eIF2α

Cell Signaling Technology

5324

1:1000 (WB)

Fen1

Proteintech

14768-1-AP

1:1000 (WB)

GAPDH

Cell Signaling Technology

2118

1:2000 (WB)

H3

Proteintech

17168-1-AP

1:1000 (WB)

HPF1

Novus Biologicals

NBP1-93973

1:1000 (WB)

OGG1

Proteintech

15125-1-AP

1:1000 (WB)

PARP1

Proteintech

66520-1-Ig

1:1000 (WB)

PARP2

Abcam

ab177529

1:500 (WB)

PheRSα

Proteintech

18121-1-AP

1:1000 (WB)

PheRSβ

Proteintech

16341-1-AP

1:1000 (WB)

Phospho-eEF2 (Thr56)

Cell Signaling Technology

2331

1:1000 (WB)

Phospho-eIF2α (Ser51)

Cell Signaling Technology

3398

1:1000 (WB)

Poly (ADP-Ribose)

Abcam

ab14459

1:1000 (WB)

PP2A C

Cell Signaling Technology

2038

1:1000 (WB)

TyrRS

Abcam

ab50961

1:1000 (WB)

XRCC1

Millipore

ABE559

1:1000 (WB)

Polymer
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Table 3.3 List of antibodies for immunofluorescence
Antibody
Company
Catalog No.
MAP2

Abcam

phosphoCell Signaling Technology
Histone H2AX
(Ser139)

Dilution

Ab5392

1:500

9178

1:400

TyrRS

Novus Biologicals

NBP1-32551

1:200

8-hydroxy-2'deoxyguanosine

Abcam

ab48508

1:200
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Table 3.4 Drug treatments
Compound
Catalog

Stock
Final
Concentration Concentration
100µM
50nM

Solvent

Rapamycin

53123, Alfa Aesar

ISRIB

5284, Tocris

250µM

5-500nM

DMSO

NMDA

0114, Tocris

50mM

50µM

PBS

MPP+ Iodide

D048, Sigma Aldrich

100mM

50µM

DMSO

A484594

324516, Millipore

100µM

100nM

DMSO

Nelfinavir
mesylate
hydrate

N0986, TCI

100µM

20-40µM

PBS

L-Tyr

194759, MP
Biomedicals

100mM

0.1-0.5mM

PBS

Dopamine HCl

H60255, Sigma
Aldrich

100mM

0.1-0.5mM

PBS

L-DOPA

A11311, Alfa Aesar

100mM

0.1-0.5mM

PBS

L-Phe

A13238, Alfa Aesar

100mM

0.1-0.5mM

PBS

D-Tyr

143865, BTC

100mM

0.5-2mM

PBS

D-Trp

215145, BTC

100mM

0.1-1mM

PBS

D-Phe

225200, BTC

100mM

0.5-2mM

PBS

6-OHDA (HBr)

25330, Cayman
Chemical

100 mM

0.1 - 0.3mM

PBS

BDNF

B3795-5UG, Sigma
Aldrich

100µg/ml

100ng/ml

PBS
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CHAPTER 4
TYROSINE INDUCES NEURONAL OXIDATIVE DNA DAMAGE
4.1 Summary
Oxidative DNA damage and associated mutations are accumulated in human aging and
neurodegenerative diseases. Aging and Alzheimer's disease (AD) both have an
increased level of L-Tyr. An acute dose of Tyr in the elderly led to an exacerbation of
age-associated cognitive decline. TyrRS activates Tyr for protein synthesis and is also
involved in DNA damage response. TyrRS is depleted in brain regions affected by the
disease through unknown mechanisms in AD patients. In this chapter, we found that
an increase in Tyr results in a decrease of TyrRS in the nucleus and neurites of cortical
neurons and an accumulation of oxidative DNA damage. However, Tyr inhibits protein
synthesis at the elongation step, dopamine (DA) - Tyr-derived neurotransmitter
induced TyrRS protein synthesis. We previously showed that Tyr inhibits TyrRSdependent activation of PARP1, a modulator of DNA repair. Taken together, these
results suggest that increased Tyr levels have causal effects on human aging and
neurocognitive disorders.
4.2 Introduction
TyrRS is a member of the evolutionarily conserved family of aaRSs that activates the
aromatic amino acid (AAA) Tyr for protein synthesis (Ibba & Soll, 2000).
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TyrRS is essential for cell survival and has a moonlighting function in DNA repair
(Blocquel et al., 2017; Cao et al., 2017b). In neurons, BDNF stimulates the de novo
synthesis of TyrRS (Liao et al., 2007).

Protein synthesis is required for long-term

memory formation (Eyman et al., 2007; P. J. Hernandez & Abel, 2008a; Kang &
Schuman, 1996), and consistently, TyrRS is depleted in the affected brain regions of
AD patients through an unknown mechanism (Xu et al., 2019). Tyr is circadian
regulated with the highest serum levels in the morning and lowest at midnight (sleep
time) (Wurtman, Rose, et al., 1968; Wurtman & Axelrod, 1967). Sleep stimulates
human brain protein synthesis (Noya et al., 2019a), memory formation (R. Huber et
al., 2004; Marshall et al., 2006), and neuronal DNA repair (Zada et al., 2019). Beyond
feeding and protein synthesis (L. B. Flexner & Goodman, 1975), Tyr is modulated by
the circadian activities of tyrosine hydroxylase (TH)(Mcgeer & Mcgeer, 1966), tyrosine
aminotransferases (TAT)(Fishman et al., 1969; Wurtman, Shoemaker, et al., 1968), and
gut microbiota(Dodd et al., 2017). Tyr rapidly crosses the blood-brain barrier (BBB)
and, therefore, is circadian regulated in the rat brain, with the lowest levels at night
(Zigmond & Wurtman, 1970). However, Tyr levels in serum increase during human
aging (Chak et al., 2019), and increased serum Tyr is a biomarker for the development
of type 2 diabetes (T2D) in humans (Wang et al., 2011), a major risk factor in the
development of dementia and AD (Li et al., 2015). Genetic mutations that cause an
increase in Tyr (tyrosinemia) or its precursor L-phenylalanine (Phe, phenylketonuria
[PKU]) manifest in the form of multiple health problems, including cognitive deficits in
children (Blau et al., 2010; Goldsmith et al., 1973; Huhn et al., 1998; Streck et al.,
2017). Moreover, treatment with Tyr exacerbates the cognitive decline in the elderly
(Bloemendaal et al., 2018; Rest et al., 2017) and in AD patients (Meyer et al., 1977),
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and dysregulated Tyr metabolism shortens lifespan in tyrosinemia (van Spronsen et
al., 1994) patients through unknown mechanisms.
Our previous studies have shown that Tyr inhibits PARP1 (Sajish & Schimmel,
2015), a major modulator of DNA repair (Caron et al., 2019; Jhanji et al., 2021a). Here,
we found that an increase in Tyr decreases TyrRS and causes neuronal oxidative DNA
damage in neurons, potentially through the inhibition of protein synthesis. However,
we discovered that the neurotransmitter derived from Tyr (dopamine) stimulates the
de novo synthesis of neuronal TyrRS. Therefore, our results provide a potential
molecular basis for the age-associated accumulation of neuronal oxidative DNA
damage and Tyr-induced cognitive impairments in elderly and AD patients.
4.3 TyrRS is decreased in the hippocampal tissue samples of human AD patients
AD decreases brain protein synthesis at the elongation step in humans (Bustany et al.,
1983; Langstrom et al., 1989; Mann et al., 1981) through unknown mechanisms. A
recently published human brain proteomic study showed decreased TyrRS and
PheRSβ levels in AD-affected brain regions (Figure 2.1). Evaluation of hippocampal
tissue lysates from human AD patients and control samples using western blots
showed a significant decrease in TyrRS (p = 0.0023, unpaired two-tailed t-test) and
PheRSβ (p = 0.0247, unpaired two-tailed t-test) proteins in AD patients in comparison
to controls (n = 7). However, the level of PheRSα protein was not affected (Figure. 4.1,
a). Furthermore, analysis of tissue-specific mRNA distribution of TyrRS in humans
(Carithers et al., 2015) from available databases (GTEx) showed that the highest
expression (transcripts per million, TPM) is in the cortical region (Figure. 4.1, b), with
TyrRS expression approximately ten times higher in the cortex (81.7 TPM) than

55

skeletal muscle (9.5 TPM) and protein levels of TyrRS do not change in an agedependent manner (Figure. 4.1, c) in mice (Takemon et al., 2021). Intriguingly, a metaanalysis of human brain transcriptomic data from AD patients did not show any
changes in the mRNA levels of TyrRS or PheRSβ (Noori et al., 2021; H. Patel et al.,
2019).
4.4 Tyrosine decreases neuronal TyrRS protein levels
Aging is the highest risk factor associated with neurodegenerative diseases, and Tyr
levels increase during human aging. Increased levels of Tyr and Phe have been shown
to inhibit aminoacyl-tRNA (Lähdesmäki, 1984; Lähdesmäki & Oja, 1975) and cause
inhibition in protein synthesis. As expected, treatment with Tyr decreased TyrRS in rat
cortical neurons (DIV 9/10) (Figure 4.2, a) with preferential effects in the nucleus and
the neurites. Although Tyr depleted PheRSβ, it did not affect the levels of PheRSα
(Figure 4.2, b). Tyr is not an essential amino acid, and it can be generated in the cell by
hydroxylation of L-phenylalanine (Phe). Phe acts as a precursor for Tyr when Tyr intake
is low. Tyr has an additional role in the synthesis of neuroactive molecules and
neurotransmitters. Tyr is hydroxylated by tyrosine hydroxylase (TH), converting it into
3,4-L-phenylalanine (L-DOPA), and this is the rate-limiting step to produce
catecholamines, DA (L-Tyr → L-DOPA → DA), epinephrine, and norepinephrine.
Similar to Tyr, Phe, 3,4-dihydroxy-L-phenylalanine (L-DOPA), and 6-hydroxydopamine
(6-OHDA), which can be generated from Tyr, also decreased the levels of PheRSβ and
TyrRS (Figure 4.2, c-e). Despite a significant decrease in TyrRS upon treatment with
Tyr, surprisingly, Tyr treatment did not result in a loss in neuronal viability (DIV9/10).
Moreover, the reduction in TyrRS protein, when treated with Tyr (200µM), was
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restored following 16-24 hrs of treatment (Figure 4.2, f), suggesting that the effect of
Tyr on TyrRS protein is reversible. Dopamine (DA), a Tyr-derived neurotransmitter, is
decreased during aging (Morgan, 1987) and in the affected brain regions of AD
patients (Jay et al., 2004b; Storga et al., 1996b). Treatment of neurons with DA
increased TyrRS protein levels, indicating that the conversion of Tyr to DA was
responsible for the reversibility in the effect of Tyr (Figure 4.2, g).
4.5 DA mimics BDNF in facilitating the de novo synthesis of TyrRS
TH catalyzes the rate-limiting step for the synthesis of DA, and this reaction is highly
regulated. Mutations in the TH gene lead to a deficiency of DA, and its homozygous
deletion is perinatally lethal in mice (Kobayashi et al., 1995; Zhou et al., 1995). DA
helps maintain synaptic plasticity (Hodas et al., 2012; Smith et al., 2005) by modulating
the synaptic proteome. Dopamine receptor activation facilitates protein synthesis by
dephosphorylation of eukaryotic elongation factor 2 (eEF2) (David et al., 2020). BDNF
is another neurotrophic factor that facilitates translation and activates eEF2. In
addition, stimulates the de novo synthesis of neuronal TyrRS(Liao et al., 2007). Thus,
we recapitulated BDNF-mediated de novo synthesis of neuronal TyrRS (Figure 4.3, c,
d). We then tested if DA would also increase neuronal TyrRS protein. We found that
DA increased the protein levels of TyrRS (Figure 4.3, a, b), and the effects of DA were
abrogated by rapamycin (Rapa, 50nM) (Figure 4.3, a). Moreover, we found that
treatment with D-Tyr, which TH does not hydroxylate, also resulted in depletion of
TyrRS, PheRSβ, and PheRSα (Figure 4.3, e) and a loss of neuronal viability (Figure 4.3,
f). D-Tyr (2mM, 24 hrs) also triggered degeneration of neurites upon treatment,
potentially due to the absence of DA generation (Figure 4.3, g). Together, these results
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suggest that while Tyr causes depletion of neuronal TyrRS, DA and BDNF facilitate its
de novo synthesis.
4.6 Pharmacological activation of protein synthesis increases TyrRS levels in rat
cortical neurons.
Previous studies have shown that ~75% knockdown of TyrRS using siRNA (siRNA TyrRS)
does not affect cell viability (Sajish & Schimmel, 2015). However, siRNATyrRS in cortical
neurons (~50% knockdown) led to neurite degeneration (Figure 4.4, a), indicating that
TyrRS is critical in maintaining neurite stability. Protein synthesis is regulated majorly
at the stages of initiation and elongation, phosphorylation of eIF2α and eEF2,
respectively, and this regulation is essential for memory and stress response (Sanchez
et al., 2019; Sharma et al., 2020; U et al., 1990). Previous studies have shown that
genetic reduction of eEF2K attenuates age-related memory deficits in mice
(Beckelman et al., 2019). We found that Tyr treatment increased phosphorylation of
eEF2 (Figure 4.4, b), possibly due to its effect on TyrRS. On analyzing brain samples of
eEF2K+/- mice, we found that TyrRS and PheRSβ were increased compared to WT
(Figure 4.4, c). Phosphorylation of eIF2α modulates motor and cognitive function
(Chesnokova et al., 2017; Eckel-Mahan et al., 2012; Sharma et al., 2020), and neuronal
survival (Moreno et al., 2012). Pharmacological activation of mRNA translation using
an integrated stress response inhibitor (ISRIB) protects against age-related memory
deficits (Krukowski et al., 2020). Consistently, treatment with ISRIB (5-50nM)
increased the protein levels of TyrRS and PheRSβ (Figure 4.4, d). Interestingly, ISRIB
also stimulated the dephosphorylation of eEF2 (Figure 4.4, d), potentially mediated
through increased levels of TyrRS. Intriguingly, despite a Tyr-dependent decrease in

58

TyrRS levels, we observed a significant increase in global translation, as shown by
increased puromycin incorporation (Figure 4.4, e). Summarily, this data indicates that
TyrRS over-expression may negatively regulate global protein synthesis. Its decrease
by tyrosine triggers rapid upregulation of controlled protein synthesis. This
dissertation, therefore, suggests that cellular levels of TyrRS and Tyr may have a
hitherto unknown function in the regulation of neuronal protein synthesis, especially
in the neurites where Tyr, DA, and BDNF modulate TyrRS levels.
4.7 L-Tyr induces oxidative DNA damage in rat cortical neurons
Neurodegenerative diseases and aging are associated with an accumulation of
oxidative DNA damage-associated mutations in neurons through unknown
mechanisms (Gabbita et al., 1998; T. Lu et al., 2004; Park et al., 2019). While sleep
deprivation causes oxidative DNA damage (Carroll et al., 2016; Park et al., 2019), sleep
stimulates neuronal DNA repair (Cheung et al., 2019a) through unknown mechanisms.
Because TyrRS moonlights in DNA repair (Cao et al., 2017c; Gao et al., 2019a), we
hypothesized that a decrease in Tyr during the night (Wurtman et al., 1967; Wurtman,
Rose, et al., 1968) might switch the function of some fraction of TyrRS from protein
synthesis to DNA repair. Conversely, aging, and neurodegenerative diseases with
increased Tyr, may inhibit TyrRS function in DNA repair. Therefore, increased Tyr and
compounds mimicking ‘Tyr conformation’ in TyrRS may induce neuronal oxidative
DNA damage. Treatment with Tyr caused an accumulation of γ-H2AX foci (a marker of
DNA damage) and 8-oxo-2'-deoxyguanosine (8-oxo-dG, a marker of oxidative DNA
damage) (Figure 4.5, a). Tyr also decreased 8-oxoguanine-DNA glycosylase (OGG1)
protein levels (Figure 4.5, b), analogous to the reported decrease of OGG1 in sleep-
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deprived humans (Cheung et al., 2019b) and in the AD brain tissues (Iida et al., 2002).
8-oxo-dG is highly mutagenic and drives a GC →AT transversions (Nakamura et al.,
1991). The frequency of mutations is higher in aging neurons (Lodato et al., 2018) and
AD brain tissues (Park et al., 2019). Consistently, γ-H2AX (Reid et al., 2021a; Shanbhag
et al., 2019b) and 8-oxo-dG (Gabbita et al., 1998) are accumulated in AD neurons.
Recent works show an essential role of histone poly-ADP-ribosylation factor (HPF1) in
DNA repair (Bonfiglio et al., 2017; Sun et al., 2021; Suskiewicz et al., 2020b). We found
that HPF1 is depleted in the hippocampus of AD patients (Figure 4.5, c), and treatment
with tyrosine also decreased HPF1 in rat cortical neurons (Figure 4.5, b). Our reanalysis of the mouse circadian proteomic (Noya et al., 2019a) and metabolomic
(Grant et al., 2019) data showed that synaptic protein level of only TyrRS (among the
aaRSs) is circadian-regulated and is inversely correlated with Tyr levels (Figure 4.5, d).
This opposing regulation of Tyr and TyrRS protein in a circadian manner further
suggests a critical role of Tyr in mediating the circadian regulation of synaptic
translation and neuronal DNA repair, potentially by regulating TyrRS levels by the
circadian regulation of DA and BDNF levels (Chung et al., 2014; Domínguez-López et
al., 2014; Liang et al., 1998; Sidor et al., 2015).
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Figure 4.1 TyrRS protein is decreased in the hippocampal region of AD patients. a.
Representative immunoblots and quantification for TyrRS and PheRSα/β using antiTyrRS and PheRSα/β antibodies in the hippocampal region of AD patients (n=7) with
age and sex-matched controls (n=7). b. Human tissue-specific mRNA distribution for
TyrRS showing highest expression in the cortex. Graph generated using data from
GTeX (Carithers et al., 2015) c. Age and sex-dependent change in TyrRS protein levels
in mice kidney. Graph generated using data published in Takemon et al. (2021).
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Figure 4.2 Tyrosine decreases nuclear and neurite levels of TyrRS. a. Tyrosine
preferentially decreases nuclear and neurite levels of TyrRS. Spectral images (scale bar,
20µm), and quantitative IF analysis of TyrRS in the nucleus, soma, and neurite of rat
cortical neurons (DIV9) using anti-TyrRS antibody after treatment with Tyr (250µM)
for 4hr. b. Representative immunoblots show total TyrRS after treatment with
Tyrosine, Phe, L-DOPA, 6-OHDA (100-300µM) for 16 hr (DIV9) c. Phenylalanine
depletes TyrRS and PheRSα/β. Primary cortical neurons were treated with Phe (100300µM) for 8 hr, and the levels of TyrRS and PheRSα/β were detected by WB analysis
using their specific antibodies. d. L-DOPA decreases neuronal TyrRS. Representative
immunoblots show TyrRS, PheRSα/β levels after treatment with increasing L-DOPA
concentrations (100-300µM) for 8hr using their specific antibodies. e. 6-OHDA
decreases the levels of TyrRS. Representative immunoblots showing TyrRS, PheRSβ
levels after treatment with increasing concentrations of 6-OHDA (100 and 200µM) for
8hr using their specific antibodies. f. Tyr effect on TyrRS protein levels is reversible.
Primary cortical neurons were treated with Tyr (200µM) for up to 24 hr, and TyrRS was
detected by WB analysis using an anti-TyrRS antibody. g. Dopamine (DA) increases
neuronal TyrRS levels. Representative immunoblots show TyrRS and PheRSα/β after
DA (100-200µM) treatment for up to 30 min in rat cortical neurons (DIV9).
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Figure 4.3 Dopamine and BDNF stimulate the de novo synthesis of TyrRS. a. Rapamycin
prevents DA-induced increase in TyrRS levels. Representative immunoblots for TyrRS
and PheRSβ after treatment with either DA (100µM) alone or in combination with
rapamycin (100nM) in rat cortical neurons (DIV9). b. Dopamine increases neuronal
TyrRS levels. Primary cortical neurons were treated with dopamine (200µM) for 2 hr
and subjected to IF analysis using an anti-TyrRS antibody to detect changes in the
protein levels of TyrRS c and d. BDNF activates the de novo protein synthesis of TyrRS.
Primary cortical neurons were treated with BDNF (50nM) for 1 hr either alone (c) or in
combination with rapamycin (Rapa., 100nM) (c), and subjected to either IF (c) or WB
(d) analysis using an anti-TyrRS antibody to detect changes in the protein levels of
TyrRS. e. D-Tyr decreases both TyrRS and PheRSβ proteins. Primary cortical neurons
were treated with D-Tyr (2.5 and 5mM) for 8 hr, and the levels of TyrRS and PheRSβ
were detected by WB analysis using their specific antibodies. f. D-Tyrosine induces
neurotoxicity. Rat cortical neurons (DIV9) were treated with either D-Tyr or D-Phe or
D-Trp (2mM) for 48 hr, and viability was assessed using MTT assay. g. D-Tyrosine
induces neurite degeneration. Representative images (scale bar, 20µm) for cortical
neurons following D-Tyr (2mM) for 24 hr treatment (MAP2 – neurite marker, magenta
and DAPI – nuclear marker, blue). Neurons were immunoassayed with anti-MAP2
antibody and quantified for neurite degeneration. All the data in the figure represents
mean ± SEM for n=3 experiments with significance measured using Student’s paired ttest.
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Figure 4.4 De novo synthesis of TyrRS is regulated at the elongation step of protein
synthesis a. TyrRS knockdown using siRNA in rat cortical neuron induces neurite
degeneration. Rat cortical neurons (DIV7) were transfected with siRNA against TyrRS
or control siRNA (75nM) for 72 hr, and the levels of TyrRS were quantified using an
anti-TyrRS antibody. Representative images (scale bar, 20µm) for cortical neurons
following siRNATyrRS treatment for 72 hr (MAP2 – neurite marker, magenta, and DAPI
– nuclear marker, blue). Neurons were immunoassayed with an anti-MAP2 antibody
and quantified for neurite degeneration. b. Tyrosine induces the phosphorylation of
eEF2. Primary cortical neurons were treated with Tyr (100-500µM) for 8 hr, and peEF2 was detected by WB analysis using anti-p-eEF2 antibody. The data represents
mean ± SEM for n=3 experiments with significance measured using Student’s paired ttest. c. Genetic reduction of eEF2K increases TyrRS in vivo. Quantitative western blots
showing the protein levels of TyrRS and PheRSβ using anti-TyrRS and PheRSβ
antibodies in the brain tissue samples from eEF2K+/- mice. d. ISRIB increases TyrRS
levels in neurons. Primary cortical neurons were treated with ISRIB (≤50nM) for 8 hr
and changes in the levels of TyrRS, PheRSβ, p-eEF2, eEF2, p-eIF2α, and eIF2α were
detected and quantified by WB analysis using their respective antibodies. e. Tyr
increases global protein synthesis. Primary cortical neurons were treated with Tyr
(200µM) for 4, 8, 16, 24hr, and the status of global protein synthesis was measured by
quantifying the levels of puromycin incorporation using an anti-puromycin antibody.
All the data in the figure represents mean ± SEM for n=3 experiments with significance
measured using Student’s paired t-test.
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Figure 4.5 Tyrosine induces oxidative DNA damage in neurons. a. Immunostaining
images (scale bar, 10µm) for DNA damage marker, pSer139-H2AX foci (γ-H2AX, green;
DAPI – nuclear marker, blue) in cortical neurons (DIV 10) after treatment with Tyr (250
µM) for 24 hr. The graph represents the average number of γ-H2AX foci per n=30
neurons per treatment condition for n = 4 experiments. Quantification for 8-oxo-dG
in rat primary cortical neurons (DIV9/10) after treatment with Tyr (500µM) for 16 hr.
b. Tyr decreases the protein levels of OGG1. Primary cortical neurons were treated
with Tyr (100-300µM) for 8 hours, and OGG1 was detected by WB analysis using an
anti-OGG1 antibody. c. HPF1 is decreased in the hippocampal region of AD patients.
Representative immunoblots and quantification for HPF1 using the anti-HPF1
antibody in the hippocampal region of AD patients (n=7) with age and sex-matched
controls (n=7). d. Synaptic TyrRS protein is circadian regulated. Graph depicting the
circadian protein levels of synaptic TyrRS and circadian levels of serum tyrosine were
generated using data from the re-analysis of the mouse circadian proteomic (Noya et
al., 2019b) and metabolomic(Eckel-Mahan et al., 2012) data.
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CHAPTER 5
OPPOSITE EFFECTS OF CIS-RSV AND TRANS-RSV ON NEURONAL DNA REPAIR AND
SURVIVAL
5.1 Summary
Resveratrol (RSV) is a natural polyphenolic molecule produced by plants in response
to stress conditions such as an injury or attack by bacterial and fungal pathogens. It
exists majorly in two isomeric forms, cis-RSV and trans-RSV. Although studied widely
for its anti-cancerous and anti-aging effects, trans-RSV can also cause neurite
degeneration, kidney toxicity, atherosclerosis, premature senescence, and
genotoxicity, partly providing a molecular basis for the divergent outcomes in various
clinical trials. Therefore, the mechanism for the protective effects of RSV remains an
enigma. In this context, we noticed that the physiological functions of cis-RSV are not
well known. We previously showed that Tyr inhibits TyrRS-mediated activation of
PARP1, a modulator of DNA repair. We now found that trans-RSV that binds to TyrRS
mimicking ‘Tyr conformation’ decreases TyrRS inhibits DNA repair and induces
neurotoxicity. Conversely, cis-RSV binds to TyrRS mimicking a ‘Tyr-free conformation,’
increases TyrRS, facilitates DNA repair and protects neurons against multiple
neurotoxic agents in a TyrRS-dependent manner. Our results thus offer a plausible
explanation for the divergent effects observed in various clinical trials using RSV.
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5.2 Introduction
Resveratrol (3,5,4'-trihydroxystilbene or RSV) is an active constituent of a cardiotonic
concoction 'Drakshasava', an Indian herbal preparation made from grapes (Paul et al.,
1999). (“Drakshasava" means "extract from grapes"). RSV is considered responsible
for the ‘French Paradox’ (Renaud & de Lorgeril, 1992; J. M. Wu et al., 2001). It is
produced by many plant species, especially grapevines, pines, and legumes, and is
abundant in peanuts, soybeans, blueberries, and pomegranates. RSV acts as a
protective agent in plants in response to stress such as injury or attack by pathogens
or UV exposure and is believed to activate their innate defense mechanism.
Interestingly, Botrytis cinerea infection in grapes increases the synthesis of RSV in the
leaf epidermis and grape skins exclusively (Jeandet et al., 1995). Furthermore, red
wine contains higher RSV amounts than white wine as it contains fermented grape
skins (Jeandet et al., 1991). In 1939, RSV was first isolated by Takaoka from Veratrum
grandiflorum O. Loes (root of the white hellebore) (Takaoka, 1939). Hence, the name
‘resveratrol’ is based on its chemical structure and the source used for its isolation (a
resorcinol derivative or polyphenol in resin from a Veratrum species). Despite
protective action in plants, ingestion of RSV could also evoke a similar protective stress
response in animals and is widely expected to overcome stressful/harmful conditions
(Baur & Sinclair, 2006), including auto-immune disorders (A. L. B. Oliveira et al., 2017).
However, RSV captured widespread scientific and public interest due to its touted anticancer (Jang et al., 1997) and anti-aging effects (Howitz et al., 2003). Unfortunately,
despite being one of the most widely studied small molecules, neither in vivo animal
models of diseases nor clinical studies demonstrate any consistent beneficial effects
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and brought disappointing/unexpected detrimental outcomes (Kjaer et al., 2017; Vang
et al., 2011).
5.3 cis-RSV and trans-RSV have opposite effects on TyrRS levels in neurons.
We previously showed that trans-RSV competes with Tyr to bind TyrRS (Sajish &
Schimmel, 2015). More importantly, we previously showed that low concentration
trans-RSV adapts its cis conformation (cis-RSV) and increases the protein levels of
TyrRS (Sajish & Schimmel, 2015). Furthermore, we previously found that cis-RSV
binding to TyrRS alters its normal function and mediates a PARP1-dependent stress
response, whereas trans-RSV mimics Tyr binding. Although cis-RSV and trans-RSV exist
in mixtures and are stable for at least six weeks at 4°C (Goldberg et al., 2002; RomeroPérez et al., 1996), and in the cell for 24 hours (Fernández-Castillejo et al., 2019), the
intracellular pool of sulfate metabolites of RSV mainly generate cis-RSV (K. R. Patel et
al., 2013). Daily supplementation of trans-RSV in diet can result in a peak plasma
concentration of 137μM (Cai et al., 2015) and an accumulation of 50-640 μM in human
tissues (K. R. Patel et al., 2013). Recent clinical studies using low-dose trans-RSV
(75mg/dose) reported cognitive benefits in post-menopausal women (Evans et al.,
2017; Thaung Zaw et al., 2020; Zaw et al., 2020), who have higher Tyr levels (Auro et
al., 2014). In contrast, clinical studies with 2,000 mg/day dose exacerbated brain
volume loss for AD patients (Turner et al., 2015), suggesting that low dose trans-RSV
(that gets converted to cis-RSV) and high dose trans-RSV (that remains in trans
conformation) evoke opposite effects. Since the brain protein level of TyrRS correlated
with cognitive performance (Johnson et al., 2020), we hypothesized that cis-RSV and
trans-RSV would have differential effects on neuronal TyrRS levels. Consistent with
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the results in clinical trials, a low dose of trans-RSV (10µM) increased TyrRS, whereas
the high dose (50µM) decreased it. However, both doses of cis-RSV (10 and 50µM)
increased TyrRS levels (Figure 5.1 a,b), indicating that while cis-RSV increases its levels,
trans-RSV depletes TyrRS levels. Interestingly, cis-RSV rescued the effects of trans-RSV
and Tyr-mediated decrease in TyrRS levels in a dose-dependent manner (Figure 5.1
d,e). High concentrations of trans-RSV decreased PheRSβ, not PheRSα levels, while cisRSV increased their levels (Figure 5.1 c). Further, cis-RSV-mediated increase in TyrRS
level was abrogated by adding cycloheximide (CHX) (Figure 5.1 g), suggesting that cisRSV stimulates the de novo synthesis of TyrRS. While cis-RSV triggered a transient
increase in the levels of p-eIF2α, trans-RSV sustained the inhibition of eIF2α (Figure
5.1 f, h), with increased phosphorylation sustained up to 8 hours. Thus, cis-RSV
increases, while Tyr and trans-RSV decrease TyrRS protein levels, potentially by
modulating its de novo synthesis.
5.4 cis-RSV activates eEF2 to facilitate the de novo synthesis of TyrRS
We found that neurotoxic agents such as N-Methyl-D-aspartate (NMDA), and the
mitochondrial toxin 1-methyl-4-phenylpyridinium (MPP+) also decreased neuronal
TyrRS after 4 hr of treatment (Figure 5.2, a); cis-RSV suppressed this effect, whereas
trans-RSV exacerbated it (Figure 5.2, a), suggesting that neuronal TyrRS is a potential
target of multiple neurotoxic agents. Interestingly, glutamate/NMDA signaling is
known to inhibit protein synthesis by phosphorylating eEF2 (Marin et al., 1997)
However, treatment with ISRIB rescues translation inhibition and protects
against neurotoxicity (Bugallo et al., 2020). We consistently found that
pharmacological activation of translation using ISRIB rescued trans-RSV mediated
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depletion of TyrRS (Figure 5.2, b), indicating that modulation of translation signaling
can potentially protect from neurotoxic effects of trans-RSV. Consistent with a
previous report (Khan et al., 2010), we also found that trans-RSV inhibited eEF2 (Figure
5.2, e), but in contrast, we found that cis-RSV activated eEF2 through
dephosphorylation (Figure 5.2, e). Similarly, treatment with an eEF2K activator
(nelfinavir) (Gassart et al., 2016) depleted neuronal TyrRS, which was rescued by cisRSV (Figure 5.2 c, d).
Furthermore, puromycin incorporation assay in the presence of cis-RSV and
trans-RSV showed that trans-RSV decreased de novo protein synthesis. In contrast,
cis-RSV has no effect (Figure 5.2, g), suggesting that cis-RSV-mediated phosphorylation
of eIF2α (Figure 5.1 f, h) may limit the overactivation of protein synthesis. To
determine the mechanism of cis-RSV-mediated activation of eEF2, we tested if cis- and
trans-RSV modulate the interaction of TyrRS with eEF2. Protein phosphatase 2A
(PP2A) is a large family of enzymes that regulate the Ser/Thr phosphorylation in
cellular processes with the highest expression in the brain (Stamatoyannopoulos et
al., 2012), known to directly dephosphorylate eEF2 at Thr56 (REDPATH et al., 1993).
We found that cis-RSV facilitated the interaction of eEF2 with TyrRS and the catalytic
subunit of PP2A (PP2A C). In contrast, trans-RSV and Tyr decreased their interaction
(Figure 5.2 f). This data suggests that cis-RSV modulates the de novo synthesis of TyrRS
at the elongation step, like BDNF (Takei et al., 2009b) and DA (David et al., 2020) that
activate eEF2 through dephosphorylation.
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5.5 cis-RSV protects against Tyr induced DNA damage
Tyr is increased in neurodegenerative diseases and the aged population and causes an
increase in oxidative DNA damage when injected into the brain (Rest et al., 2017;
Streck et al., 2017). Therefore, we hypothesized that increased Tyr levels and
compounds that mimic ‘Tyr conformation’ in TyrRS might induce neuronal oxidative
DNA damage. Conversely, compounds that mimic a ‘Tyr-free conformation’ in TyrRS
may shift its function to facilitate neuronal DNA repair. To test this possibility, we
treated neuronal cultures with cis-RSV, which evokes a ‘Tyr-free conformation’(Jhanji
et al., 2021a), or trans-RSV, which mimics a ‘Tyr conformation’ in TyrRS (Sajish &
Schimmel, 2015). Treatment with Tyr resulted in the accumulation of γ-H2AX foci (a
marker of DNA damage) and 8-oxo-2'-deoxyguanosine (8-oxo-dG, a marker of
oxidative DNA damage) (Figure 4.4, a). While cis-RSV rescued Tyr-induced
accumulation of γ-H2AX, and 8-oxo-dG, trans-RSV itself caused the accumulation of γH2AX and 8-oxo-dG (Figure 5.3, a, b). cis-RSV rescued Tyr-mediated depletion of OGG1
(Figure 5.3, d). Similarly, cis-RSV also protected against D-Tyr-mediated neurotoxicity
and neurite degeneration but not trans-RSV (Figure 5.3, c, e). Emerging works show a
critical role of histone poly-ADP-ribosylation factor (HPF1) in PARP1-dependent DNA
repair (Sun et al., 2021; Suskiewicz et al., 2020b). Since Tyr decreases HPF1 levels
(Figure 4.4, b), we determined the effect of cis-and trans-RSV on HPF1 levels. Although
cis-RSV did not affect the HPF1 levels, treatment trans-RSV decreased the levels of
HPF1 (Figure 5.3, h), indicating similar mechanisms for Tyr-mediated and trans-RSV
accumulation of oxidative DNA damage in neurons. To obtain direct evidence for DNA
damage, we also conducted a comet assay. We treated cortical neurons with cis-RSV,
trans-RSV, and L-tyrosine either alone or in combination. We found that both trans71

RSV, L-tyrosine, and their combination significantly increased DNA damage as
measured by the increase in % of DNA in the tail (Figure 5.5, d).
5.6 cis-RSV is neuroprotective and trans-RSV is neurotoxic.
Since cis- and trans-RSV showed opposite effects on neuronal oxidative DNA damage,
we hypothesized that they might have differential effects on neuronal survival under
stress conditions. We analyzed cis- and trans-RSV effects on the survival of rat primary
cortical neurons exposed to different stress agents to test this hypothesis. As
expected, the effect of trans-RSV on NMDA-mediated neurotoxicity showed a
concentration-dependent dual response, where low concentrations of trans-RSV
(≤10µM) evoked protective effects, but the higher concentrations (≥25µM)
exacerbated the toxicity (Figure 5.4, a). In contrast, cis-RSV protected against NMDAmediated toxicity in a concentration-dependent manner (Figure 5.4, b). Hence, the
concentration-dependent dual response of trans-RSV on neuroprotection is
consistent with trans to cis conversion at low concentrations (Fernández-Castillejo et
al., 2019), increasing TyrRS levels, and the retention of ‘trans/Tyr conformation’ at
high concentrations (Jhanji et al., 2021a), causing TyrRS depletion (Figure 5.1, a, b).
We also found that cis-RSV (50 µM) suppressed the neurotoxicity induced by a DNAdamaging agent (etoposide, ETO) oxidative stress (H2O2), and mitochondrial inhibition
(MPP+) but trans-RSV (50 µM) did not protect against these neurotoxic agents (Figure
5.4, d, e, f). To test if the observed effects of cis- and trans-RSV on neurotoxicity are
mediated via TyrRS, we carried out siRNA knockdown of TyrRS (siRNATyrRS) in rat
cortical neurons. TyrRS knockdown (Figure 5.4, c) blunted the neuroprotective effects
of cis-RSV but did not diminish the toxicity of trans-RSV (50 µM) upon NMDA
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treatment (Figure 5.4, c). These results suggest that the neuroprotective effect of cisRSV (and low-dose trans-RSV) is TyrRS dependent. However, the neurotoxic effect of
trans-RSV is TyrRS independent. Moreover, we found that trans-RSV (50 µM) by itself
was neurotoxic in the rat primary cortical neuron culture. In contrast, cis-RSV
protected against the neurotoxicity induced by trans-RSV in a dose-dependent
manner (Figure 5.4, g). Furthermore, a high concentration of trans-RSV and D-Tyr
increased the levels of cleaved caspase-3 (a marker of apoptosis) in rat primary cortical
neurons (Figure 5.4, h, i). In contrast, cis-RSV decreased the levels of caspase-3
cleavage (Figure 5.4, h). Thus, while trans-RSV is neurotoxic and causes DNA damage,
cis-RSV can protect against neurotoxic and DNA damaging agents.
5.7 cis-RSV and trans-RSV have opposite effects on the auto-PARylation of PARP1.
We previously showed that Tyr inhibits the auto-PARylation of PARP1 (Sajish &
Schimmel, 2015) while cis-RSV induced a ‘Tyr-free conformation’ in TyrRS (Jhanji et al.,
2021a) to stimulate the auto-PARylation. We analyzed the effects of cis- and transRSV on the auto-PARylation of PARP1 to validate the differential effect of TyrRS
conformation on PARP1. As expected, a low concentration of trans-RSV (5µM), which
converts to cis-RSV in solution (Fernández-Castillejo et al., 2019), and cis-RSV
stimulated the auto-PARylation of PARP1 (Figure 5.5, a). In contrast, higher
concentrations of trans-RSV (≥25µM) inhibited the auto-PARylation of PARP1 (Figure
5.5, b). It is interesting to note that the apparent Ki value of trans-RSV-mediated
inhibition of Tyr activation by TyrRS in an ATP-PPi exchange assay (Tyr + ATP → TyrAMP + PPi) was ~25µM (Sajish & Schimmel, 2015), the lowest concentration of transRSV that significantly inhibits the auto-PARylation of PARP1 (Figure 5.5, b). We
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previously showed that Tyr inhibits auto-PARylation-dependent acetylation of
proteins (Sajish & Schimmel, 2015). Furthermore 500 mg/day dose of trans-RSV
(68.5µM peak plasma concentration) inhibited the acetylation of H3 at lysine 56 (AcK56-H3) in humans (Palazzo et al., 2018). Consistently, trans-RSV (≥25µM) inhibited
H3 acetylation at lysine 9 and 56 (Ac-K9-H3 and Ac-K56-H3) (Figure 5.5, a, b), whereas
cis-RSV increased the acetylation of H3 lysine 9 (Ac-K9-H3). Furthermore, TyrRS
knockdown diminished the effects of low-concentration (5 µM) trans-RSV and cis-RSV
(25µM) on the auto-PARylation of PARP1 (Figure 5.5, d).
5.8 cis-RSV stimulates the deADP-ribosylation of neuronal chromatin.
DNA damage activates PARP1/HPF1-dependent serine ADP-ribosylation of histones
(Bonfiglio et al., 2017), and removal of this modification is essential for neuronal
survival (Mashimo et al., 2013). Notably, the brain samples of AD patients were
reported to have increased levels of nuclear ADP-ribosylation (Love et al., 1999).
Although auto-PARylation dissociates PARP1 from the chromatin (Kim et al., 2004),
HPF1 inhibits the auto-PARylation and increases trans-PARylation of chromatin (Sun
et al., 2021; Suskiewicz et al., 2020b). Because trans-RSV inhibited the autoPARylation, we hypothesized that trans-RSV would increase PARP1-dependent transPARylation of the chromatin. As expected, trans-RSV increased the association of
PARP1 with chromatin and increased the levels of PARylated proteins in the chromatin
fraction (Figure 5.6, a). Further, low concentrations of trans-RSV (≤10µM) and cis-RSV
prevented the interaction of PARP1 with histone H3, while the higher concentrations
(≥25µM) of trans-RSV increased it (Figure 5.6, e). Although cis-RSV-mediated autoPARylation of PARP1 resulted in its removal from the chromatin, unexpectedly, we
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found that cis-RSV activated the deADP-ribosylation of the chromatin fraction along
with higher levels of TyrRS (Figure 5.6, a). ADP-ribosyl-acceptor hydrolase 3 (ARH3)
regulates poly (ADP-ribose) degradation (Mashimo et al., 2013), and as expected, cisand trans-RSV had differential effects on the recruitment of ARH3 to the chromatin
(Figure 5.6, a). Despite having increased levels of nuclear ADP-ribosylation, the levels
of ARH3 remained unchanged in the hippocampal region of human AD patients (Figure
5.6, g), indicating that ARH3 may not be functional in human AD brain tissues in the
absence of TyrRS. Consistently, we found that TyrRS interacted with ARH3 (Figure 5.6,
c), suggesting a potential novel role of TyrRS in the removal of nuclear poly (ADPribose), facilitating neuronal DNA repair and survival.
5.9 ‘Trapped’ PARP1 inhibits DNA repair and mediates the neurotoxic effects of
trans-RSV.
Suicidal crosslinking of PARP1 to the damaged DNA (Prasad et al., 2014) causes
cytotoxicity (Hopkins et al., 2019), and therefore, cell survival depends on removing
‘trapped’ PARP1 on the broken DNA by either ablation (Yang et al., 2004) or autoPARylation (Satoh & Lindahl, 1992; Zahradka & Ebisuzaki, 1982). Because trans-RSV
caused DNA damage (Figure 5.3, a) and inhibited the auto-PARylation of PARP1 (Figure
5.5, a), and ablation of PARP1 can rescue ‘trapped’ PARP1-mediated neurotoxicity
(Eliasson et al., 1997; Hoch et al., 2017), we hypothesized that trans-RSV-mediated
neurotoxicity is exerted through ‘trapped’ PARP1 on the damaged DNA. Consistently,
small interfering RNA (siRNA) knockdown of PARP1 (siRNAPARP1) protected against
trans-RSV-mediated neurotoxicity but did not interfere with the effect of cis-RSV
(Figure 5.6, d), indicating that ‘trapped’ PARP1 mediates the neurotoxic effects of
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trans-RSV. On the other hand, we found that cis-RSV facilitated the recruitment of
DNA repair factors such as HPF1 and OGG1 to the chromatin while trans-RSV
prevented their recruitment (Figure 5.6, f). PARP1 inhibits flap endonuclease (FEN1)dependent long patch base excision repair (BER) (Sukhanova et al., 2010), and
consistently, cis-RSV decreased the recruitment of FEN1 (Figure 5.6, f), indicating a
potential role of TyrRS/ARH3-dependent deADP-ribosylation of PARP1 in limiting long
patch BER. As further evidence of DNA repair, we assessed whether DNA synthesis
occurred following cis- or trans-RSV treatment. The incorporation of nucleoside
analogs into DNA from neurons was previously used as a readout of neuronal DNA
repair (Reid et al., 2021), and depletion of PARP1 or inhibitors of PARP1 increases the
incorporation of nucleoside analogs (W. Wu et al., 2021). In agreement with the
observation that ‘trapped’ PARP1 on the DNA impairs base excision repair (BER)
(Sukhanova et al., 2005), trans-RSV prevented the incorporation of the nucleoside
analog CldU into DNA fibers isolated from neurons (Figure 5.6, b). However, cis-RSV
reduced the CldU incorporation suggesting the activation of PARP1-dependent short
patch BER (W. Wu et al., 2021), potentially through the displacement of FEN1 (Figure
5.6, f) and increased recruitment of unmodified PARP1 to the chromatin (Figure 5.6,
a) that limits DNA resection (Caron et al., 2019). This decrease also indicates that cisRSV might activate other DNA repair pathways that enhance discrimination against
the incorporation of nucleoside analogs into the genome, which requires future
explorations. Together these results show that cis-and trans-RSV may have opposite
effects on TyrRS-regulated auto-PARylation (Jhanji et al., 2021a; Sajish & Schimmel,
2015) and DNA repair (Cao et al., 2017c).
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Figure 5.1 cis-RSV modulates the de novo synthesis of TyrRS at the elongation step of
protein synthesis. a. cis-and trans-RSV have opposite effects on neuronal TyrRS protein.
Representative spectral images (scale bar, 20µm) of the protein level of neuronal
TyrRS in rat cortical neurons (DIV10) following treatment with either cis-RSV or transRSV for 16 hr (MAP2 – neurite marker, magenta; DAPI – nuclear marker, blue; TyrRS –
red-yellow spectral image). b. Low and high concentrations of trans-RSV (10 and
50µM) have opposite effects on TyrRS, and low concentration trans-RSV mimics cisRSV to increase the protein levels of TyrRS. Representative immunoblots and spectral
images (scale bar, 20µm) and quantification for TyrRS after treatment with cis-and
trans-RSV (10 and 50µM) for up to 16 hr in rat cortical neurons (DIV9). c. cis- and transRSV have opposite effects on neuronal PheRSβ. Representative immunoblots and
quantification for PheRSα/β after treatment with cis-and trans-RSV (5-50µM) for up
to 16 hr in rat cortical neurons (DIV9). d. cis-RSV protects neurons against Tyrmediated depletion of TyrRS. Primary cortical neurons were treated with Tyr (200µM)
alone or combined with cis-RSV for 8 hours and detected TyrRS using an anti-TyrRS
antibody. e. cis-RSV protects neurons against a trans-RSV-mediated decrease in TyrRS
levels. Representative immunoblots showing the protein levels of TyrRS after
treatment with trans-RSV (50µM) alone or in combination with different doses of cisRSV for 16 hr in rat cortical neurons (DIV9). f. cis- and trans-RSV have differential
effects on the phosphorylation of eIF2a. Primary cortical neurons were treated with
cis- and trans-RSV (5-50µM) for 2 hr and p-eIF2α were detected by WB analysis using
an anti-p-eIF2α antibody. g. cis-RSV stimulates the de novo synthesis of neuronal
TyrRS. Spectral images (scale bar, 20µm) and quantitative IF analysis using an antiTyrRS antibody. Primary cortical neurons were treated with cis-RSV (50µM) for 30
minutes alone or with CHX (100µM). h. trans-RSV sustains the levels of p-eIF2a while
the effect of cis-RSV is transient. Primary cortical neurons were treated with cis- and
trans-RSV (25µM) for up to 8 hr. Changes in p-eIF2α were detected by WB analysis
using an anti-p-eIF2α antibody. The effect of p-eIF2α was also measured using the
expression levels of ATF4.
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Figure 5.2 Neurotoxic agents decrease TyrRS levels in neurons. a. cis-RSV prevents, and
trans-RSV exacerbates the decrease in the levels of TyrRS by neurotoxic agents.
Representative spectral images (scale bar, 20µm) and quantification for neuronal
TyrRS after treatment with neurotoxic agents (50µM NMDA or 100µM MPP+) for 4 hr
in combination with cis- and trans-RSV (50µM) in rat cortical neurons (DIV9). The
graphical representation is for mean ± SEM TyrRS protein levels with statistical
significance calculated using the Student’s paired t-test. b. ISRIB protects neurons
against trans-RSV-mediated depletion of TyrRS. Primary cortical neurons were treated
with trans-RSV (25µM) alone or in combination with ISRIB (10nM) for 8 hr, and
changes in the levels of TyrRS were detected by WB. c. Nelfinavir (eEF2K activator)
depletes neuronal TyrRS. Primary cortical neurons were treated with nelfinavir (2040µM) for 8 hr, and changes in the levels of TyrRS, PheRSβ, and p-eEF2 were detected
by WB analysis using their corresponding antibodies. d. cis-RSV protects neurons
against nelfinavir-mediated depletion of TyrRS. Primary cortical neurons were treated
with nelfinavir (20µM) alone or combined with cis-RSV for 8 hours. TyrRS was detected
by WB analysis using an anti-TyrRS antibody. e. cis- and trans-RSV have opposite
effects on the phosphorylation of eEF2. Primary cortical neurons were treated with cisand trans-RSV (5-50µM) for 8 hr, and p-eEF2 was detected by WB analysis using an
anti-p-eEF2 antibody. f. cis-RSV facilitates the interaction of PP2A with eEF2. Primary
cortical neurons were treated with cis- and trans-RSV (50µM) or Tyr (200µM) either
alone or with cis-RSV. In addition, immunoprecipitated eEF2 was probed for its
interaction with PP2A and TyrRS using their specific antibodies. g. trans-RSV inhibits
global protein synthesis. Primary cortical neurons were treated with cis-and trans-RSV
(5-50µM) for 1hr. The status of global protein synthesis was measured by quantifying
the levels of puromycin incorporation using an anti-puromycin antibody. All the data
in the figure represents mean ± SEM for n=3 experiments with significance measured
using Student’s paired t-test.
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Figure 5.3 Tyrosine induces oxidative DNA damage in neurons, and cis-RSV protects
neurons against it. a. cis-RSV and trans-RSV have opposite effects on Tyr-mediated
accumulation of γ-H2AX. Immunostaining images (scale bar, 10µm) for DNA damage
marker, pSer139-H2AX foci (γ-H2AX, green; DAPI – nuclear marker, blue) in cortical
neurons (DIV10) after treatment with cis- and trans-RSV (50µM) alone or in
combination with Tyr (250 µM) for 24 hr. The graph represents the average number
of γ-H2AX foci per n=30 neurons per treatment condition for n = 4 experiments. b. cisand trans-RSV have opposite effects on Tyr-mediated induction of the oxidation level
of neuronal DNA. Quantification of the levels of 8-oxo-dG in rat primary cortical
neurons (DIV9/10) after treatment with Tyr (500µM) either alone or in combination
with cis or trans-RSV (50µM) for 16 hr. c. cis-RSV protects neurons against D-Tyrosineinduced toxicity. Rat cortical neurons (DIV9) were treated with either D-Tyr alone or
combined with cis or trans-RSV (50µM) for 48 hours, and viability was assessed using
MTT assay. d. Tyr decreases the protein levels of OGG1. Primary cortical neurons were
treated with Tyr (100-300µM) for 8 hours, and OGG1 was detected by WB analysis
using an anti-OGG1 antibody. e. D-Tyrosine and trans-RSV induce neurite
degeneration. Representative images (scale bar, 20µm) for cortical neurons following
D-Tyr or cis-RSV and trans-RSV (50µM) for 24 hr treatment (MAP2 – neurite marker,
magenta, and DAPI – nuclear marker, blue). Neurons were immunoassayed with an
anti-MAP2 antibody and quantified for neurite degeneration. f. trans-RSV decreases
HPF1 protein levels. Representative immunoblots and quantification for HPF1 and
histone H3-Serine-ADPR using anti-HPF1 and anti-H3-Ser10-ADPR antibodies,
respectively in cortical neurons after treatment with cis-and trans-RSV (25-50µM)
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Figure 5.4. cis- and trans-RSV have opposite effects on neuronal survival under stress.
a. trans-RSV has opposite effects on neuronal survival under NMDA-mediated
neurotoxicity. Rat cortical neurons (DIV9) were treated with NMDA (50µM for 5 min)
and then with trans-RSV (5-50µM) for 24 hr. Cells were then exposed to NMDA
(500µM for 5 min) and viability was assessed using MTT assay after 24 hr. b. cis-RSV
provides dose-dependent neuroprotection against NMDA-mediated neurotoxicity. Rat
cortical neurons (DIV9) were treated with NMDA (50µM for 5 min) and then with cisRSV (5-50µM) for 24 hr. Cells were then exposed to NMDA (500µM for 5 min) and
viability was assessed using MTT assay after 24 hr. c. TyrRS knockdown blunts the
neuroprotective effects of cis-RSV and exacerbates the neurotoxicity of trans-RSV. Rat
cortical neurons (DIV7) were transfected with TyrRS or control siRNA (75nM) and then
treated with cis-RSV (50µM) or trans-RSV (5, 10, 50µM) for 24 hr. Neurons were then
exposed to excitotoxic NMDA (500µM for 5 min), and viability was assessed using MTT
assay after 24 hr. g. cis-RSV protects from trans-RSV-mediated neurotoxicity. Rat
cortical neurons (DIV 8) were treated with trans-RSV alone or combined with different
doses of cis-RSV (10-50µM) for 48 hr, and viability was measured using MTT assay. df. Only cis-RSV protects neurons against etoposide (d), H2O2 (e) and MPP+(f) toxicity.
Rat cortical neurons (DIV9) were exposed to 5µM etoposide (ETO), 400µM H 2O2, or
10µM MPP+ for 24 hr after pre-treatment with cis-RSV or trans-RSV (50µM) for 16 hr.
Cell viability was assessed using MTT assay g. cis-RSV and low dose trans-RSVdependent auto-PARylation of PARP1 is TyrRS dependent. Rat cortical neurons (DIV7)
were transfected with control and TyrRS siRNA followed by treatment with cis- (25µM)
and trans-RSV (5µM) for 15 min and immunoblotting and quantification using the
specific antibodies for PARylation, PARP1 and TyrRS. h. trans-RSV and D-Tyr induce
neuronal apoptosis. Immunoblots showing the levels of cleaved caspase-3 in rat
cortical neurons (DIV9/10) after the treatment with cis- and trans-RSV (25 and 50µM)
for 24 hr and D-Tyr (2mM) for 16 hr. The data in the figure represent mean ± SEM for
n=3 experiments with significance measured using Student’s paired t-test.
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Figure 5.5. Low concentration trans-RSV mimics cis-RSV in stimulating PARP1
activation a,b. cis-RSV and trans-RSV have opposite effects on the auto-PARylation of
PARP1. Representative immunoblot images and quantification using specific
antibodies for PARylation, PARP1, Ac-K9-H3, Ac-K56-H3 levels after treatment of
cortical neurons (DIV9) with cis- and trans-RSV for 15 min (* indicates p ≤0.01). c. cisRSV and low dose trans-RSV-dependent auto-PARylation of PARP1 is TyrRS dependent.
Rat cortical neurons (DIV7) were transfected with control and TyrRS siRNA followed
by treatment with cis- (25µM) and trans-RSV (5µM) for 15 min and immunoblotting
and quantification using the specific antibodies for PARylation, PARP1, and TyrRS. d.
Comet assay measuring the extent of double-stranded DNA breaks induced by tyrosine
and trans-RSV. Rat cortical neurons (DIV9-10) were treated with cis-RSV (50µM),
trans-RSV (50µM), L-Tyr (1mM) either alone or in combination for 1 hr and the
percentages of DNA in the comet tail was quantified as described in the Methods. The
data in the figure represents mean ± SEM for n=3 experiments with significance
measured using Student’s paired t-test.
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Figure 5.6 cis- and trans-RSV have opposite effects on auto-PARylation of PARP1 and
neuronal DNA repair. a. cis-RSV removes auto-PARylated PARP1 from chromatin and
trans-RSV 'traps' PARP1 onto the chromatin. Representative immunoblots and
quantification from chromatin fraction of cortical neurons (DIV9) depicting PARP1 and
PAR, ARH3, TyrRS after treatment with cis- and trans-RSV (50µM) for 1 hr. b. transRSV inhibits nucleoside incorporation in a DNA fiber assay. Cortical neurons (DIV9/10)
were treated with cis-or trans-RSV (50µM) for 8 hr followed by a 30 min pulse labeling
using 50µM of nucleoside analog, CldU (5-chloro-2'-deoxyuridine). DNA fiber assay
was performed according to the published protocol followed by immunostaining for
single-stranded (ss) DNA (red) and CldU (green). The incorporation of CldU in DNA
during the repair process was assessed using ImageJ by counting the number of CldU
positive DNA fibers for a total of 300 fibers per condition. c. TyrRS interacts with ARH3.
Immunoprecipitated (IP) TyrRS from cortical neurons (DIV9) was immunoblotted (IB)
using anti-TyrRS and anti-ARH3 antibodies to detect the interaction of TyrRS with
ARH3. Total TyrRS and ARH3 were detected by WB. d. siRNA knockdown of PARP1
rescues trans-RSV-mediated neurotoxicity. Rat cortical neurons (DIV7) were
transfected with siRNA against PARP1 (siRNAPARP1) or control siRNA (75nM) and then
treated with cis-RSV (50µM) or trans-RSV (50µM) for 72 hr. Neuronal viability was
assessed and quantified using an MTT assay. The knockdown was verified using
immunoblot and quantified using specific antibodies for PARP1. e. cis-RSV prevents,
and trans-RSV increases the interaction of PARP1 with histone H3. Representative
immunoblots and quantification of the interaction of H3 with PARP1. Cortical neurons
(DIV9) were treated with cis- and trans-RSV (5-50µM) for 30 min and PARP1 was
immunoprecipitated (IP) using an antibody against PARP1. The interaction of PARP1
with H3 was determined using an anti-H3 antibody. f. cis-RSV and trans-RSV have
differential effects on chromatin recruitment of DNA repair proteins. Representative
immunoblots using specific antibodies and quantification from chromatin fraction of
cortical neurons (DIV9) depicting HPF1, OGG1, FEN1, and PARP2 after treatment with
cis- and trans-RSV (50µM) for 1 hr. g. ARH3 levels are not affected in the hippocampal
tissues of human AD patients. Representative immunoblots and quantification for
ARH3 using the anti-ARH3 antibody in the hippocampal region of AD patients (n=7)
with age and sex-matched controls (n=7). All graphs represent mean ± SEM with
statistical significance calculated using Student’s paired t-test.
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Figure 5.7 Proposed mechanism of cis-RSV-mediated neuroprotection and trans-RSVmediated neurotoxicity. cis-RSV bound TyrRS mediates auto-poly-ADP-ribosylation of
PARP1 facilitating its removal from chromatin, allowing for recruitment of DNA repair
proteins, helping in efficient DNA repair. Trans-RSV traps PARP1 on the chromatin,
leading to an accumulation of DNA damage, resulting in neurotoxic effects.
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CHAPTER 6
CONCLUSIONS AND FUTURE DIRECTIONS
6.1 Conclusions
Aging is associated with an increased incidence of most chronic metabolic and
neurodegenerative diseases. Tyr levels regulated in a circadian manner increase with
aging and cognitive decline. This dissertation explored the mechanism for Tyr
mediated negative regulation of neuronal TyrRS, providing a potential molecular basis
for circadian modulation of synaptic TyrRS (Figure 4.5, d) (Noya et al., 2019b), higher
oxidative DNA damage in aged neurons and under neurodegenerative disease
conditions, tyrosine-mediated cognitive impairment, and the decreased protein
synthesis in human AD brain tissue samples. Although it is counter-intuitive, elevated
levels of tyrosine are inhibitory for the de novo synthesis of TyrRS and translation at
the elongation step, for which it is requisite, it is also important to note that elevated
levels of tyrosine facilitate assembly of eIF4F and phosphorylation of S6K1. These
observations suggest that TyrRS may be a potential modulator of translation initiation
by regulating the assembly of eIF4F. Interestingly, a Tyr accumulating Neurospora
crassa mutant is sensitive to Tyr (Wolfinbarger & Marzluf, 1976), and its detoxification
is also essential for the survival of hematophagous insects (Sterkel et al., 2016).
Regulation of protein synthesis at the elongation step contributes to synaptic
plasticity, making it conceivable that tyrosine-mediated regulation of TyrRS might be
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an evolutionary conserved negative feedback regulatory mechanism of protein
synthesis exploited by neurons. Interestingly, calorie restriction (CR) significantly
lowers only tyrosine levels among the AAAs and improves memory in humans.
Similarly, sleep that decreases tyrosine levels stimulates brain protein synthesis,
memory formation, and neuronal DNA repair. Interestingly, exercise stimulates the
production of BDNF, and DA is also known to activate PARP1-dependent DNA repair
and stimulates protein synthesis through activation of eEF2 in humans.
Although increased levels of branched-chain amino acids (BCAAs) are
associated with metabolic disorders, in this context, it is interesting to note that the
levels of BCAAs are decreased in AD and ASD. However, an increased level of tyrosine
is associated with both neurocognitive and metabolic disorders. These observations
suggest that decreased tyrosine may be an endogenous stimulator of TyrRS-mediated
auto-PARylation of PARP1 and associated with signaling events dysregulated during
aging and under various neurocognitive and metabolic disorders. Therefore, tyrosinemediated induction of 8-oxo-dG and γH2AX (Fig. 5.3 a, b) and tyrosine-mediated
depletion of TyrRS shown here may have causal effects in human aging, motor,
cognitive, and metabolic disorders (Fig. 6.1).
This dissertation also provides a potential explanation for high dose (1000mg
twice a day, i.e; 137µM plasma concentration of trans-RSV/dose) trans-RSV-mediated
brain volume loss in AD patients and trans-RSV (200mg twice a day, i.e; 27.5µM plasma
concentration of trans-RSV/dose)-mediated worsening of memory performance in
schizophrenia, like high concentrations of trans-RSV that deplete neuronal TyrRS and
exacerbate neurotoxic effects in our study. Recent clinical trials showed that low-dose
trans-RSV (50mg/dose, 6µM peak plasma concentration) gets converted to cis-RSV
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and induces a ‘tyrosine-free’ conformation in TyrRS, protecting against human heart
failure where high tyrosine levels negatively correlate with survival (Table 2.1). In
contrast, high-dose trans-RSV (1000mg/dose, 137µM peak plasma concentration)
maintains ‘trans/tyrosine-like’ conformation in TyrRS and induces oxidative DNA
damage (Fig. 5.3, a and b), increasing the CVD risk. Consistently, oxidative DNA
damage is elevated in CVD and patients with heart failure. Because cis-RSV evokes a
‘tyrosine-free’ conformation in TyrRS and CR decreases serum tyrosine levels, our
results presented here may suggest that by mimicking a ‘tyrosine-free’ conformation
in TyrRS, cis-RSV would have potentially mediated CR-like protective effects while
inducing a ‘tyrosine-like’ conformation in TyrRS, trans-RSV would have potentially
caused the exacerbation of the pathological outcomes in clinical trials. Therefore, in
addition to a plausible explanation for the apparent benefits of low doses of transRSV, our study suggests that cis-RSV or compounds that use cis-RSV conformation as
a pharmacophore may help in the chronotherapy of age-associated neurological
disorders and potentially degenerative and metabolic diseases of other tissues.
6.2 Future Directions
PARP1 activity is higher in centenarians and is also required for forming long-term
memory. Although HPF1-dependent PARP1 activation (Langelier et al., 2021;
Suskiewicz et al., 2020a) is known to play a role in DNA repair, future studies are
required to determine if HPF1-dependent serine-PARylation by PARP1 would be
involved in the repair of neuronal activity-dependent DNA damage.
Although cis-RSV and ISRIB increased protein levels of TyrRS, there are
limitations to their use as therapeutics due to less bioavailability associated with cis-
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RSV and neurotoxic effects of ISRIB in mice studies (Briggs et al., 2017; Johnson & Kang,
2016). Therefore, developing novel molecules targeting TyrRS may provide druggable
small molecules. Although ISRIB is known to improve cognitive performance,
currently, the involvement of TyrRS in ISRIB-mediated cognitive performance remains
unexplored. Moreover, there is no direct evidence indicating the involvement of TyrRS
in cognitive performance. Future studies using brain-specific overexpression and
deletion of TyrRS are essential to determine if neuronal TyrRS plays a causal role in
cognition and memory formation.
Finally, ISRIB is known to mitigate the stress-response mediated induction of
activating transcription factor 4 (ATF4) (Sidrauski et al., 2015). Intriguingly, TyrRS is
among the ATF4 target genes upregulated during integrated stress response (Han et
al., 2013). Therefore, the ISRIB-mediated increase in TyrRS cannot be explained
through existing mechanisms of action. Our novel findings thus indicate the existence
of an unknown physiological target of ISRIB that increases neuronal TyrRS protein at
low nano molar levels. Moreover, whether an ISRIB-mediated increase in TyrRS would
influence neuronal DNA repair through PARP1 activation remains explored in future
studies.
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Figure 6.1. Potential mechanism of Tyr-mediated induction of age-associated
neurocognitive disorders and genomic instability. Age-dependent elevated tyrosine
levels and a resulting decrease in TyrRS protein levels in Alzheimer’s disease result in
the accumulation of DNA damage and associated genomic instability. Memorystimulating factors and exercise stimulate de novo synthesis of TyrRS, helping in DNA
repair and protein synthesis. trans-RSV causes exacerbation in disease pathology for
Alzheimer’s and increases DNA damage. cis-RSV and ISRIB stimulated de novo
synthesis of TyrRS will improve cognitive function and facilitate DNA repair.
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